UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
ON
FORM 10-12G/A
AMENDMENT
No. 1
TO FORM 10-B
GENERAL
FORM FOR REGISTRATION OF SECURITIES
Under
Section 12(b) or (g) of the Securities Exchange Act of 1934
Commission
file number 000-1426567
LABWIRE,
INC.
(Name of
Registrant in its charter)
Nevada
|
|
37-1501818
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification No.)
|
1514
FM 359, Brookshire, Texas 77423
(Address
of principal executive offices) (Zip Code)
Issuer’s
telephone number:
(281)
934-3153
Securities
to be registered under Section 12(b) of the Act:
None
Securities
to be registered under Section 12(g) of the Act:
Common
Stock - $.001 par value
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,”
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the
Exchange Act.
Large
accelerated
filer Accelerated
filer
Non-accelerated
filer Smaller
reporting company
x
Labwire,
Inc.
FORM
10
TABLE OF
CONTENTS
|
|
Page
|
PART
I
|
|
|
Item
1
|
Description
of Business
|
4
|
Item
1A
|
Risk
Factors
|
9
|
Item
2
|
Financial
Information
|
14
|
Item
3
|
Description
of Property
|
20
|
Item
4
|
Security
Ownership of Certain Beneficial Owners and Management
|
20
|
Item
5
|
Directors
and Executive Officers
|
21
|
Item
6
|
Executive
Compensation
|
23
|
Item
7
|
Certain
Relationships and Related Transactions and Director
Independence
|
23
|
Item
8
|
Legal
Proceedings
|
24
|
Item
9
|
Market
Price of and Dividends on the Registrant’s Common Equity and Other
Stockholder Matters
|
24
|
Item
10
|
Recent
Sales of Unregistered Securities
|
25
|
Item
11
|
Description
of Securities to be Registered
|
26
|
Item
12
|
Indemnification
of Directors and Officers
|
27
|
Item
13
|
Financial
Statements and Supplementary Data
|
28
|
Item
14
|
Changes
in and Disagreements with Accountants
|
28
|
Item
15
|
Financial
Statements and Exhibits
|
28
|
Signatures
|
|
30
|
EXPLANATORY
NOTES
In this
Form 10, pursuant to Rule 8-02 of Regulation S-X, we are including an audited
consolidated balance sheet as of the end of each of the most recent two fiscal
years along with audited consolidated statements of income, cash flows and
changes in stockholders’ equity for each of the two fiscal years preceding the
date of the most recent audited balance sheet. We have also included
an unaudited consolidated balance sheet as of September 30, 2008 along with
unaudited consolidated statements of income, cash flows and changes in
stockholders’ equity for the three-months and nine-months ended September 30,
2008.
We are
filing this General Form for Registration of Securities on Form 10 to
register our common stock, par value $.001, pursuant to Section 12(g) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
We are
now subject to the requirements of Regulation 13A under the Exchange Act,
which will require us to file annual reports on Form 10-K, quarterly reports on
Form 10-Q, and current reports on Form 8-K, and we will be required to comply
with all other obligations of the Exchange Act applicable to issuers filing
registration statements pursuant to Section 12(g).
Unless
otherwise noted, references in this registration statement to “Labwire,” the
“Company,” “we,” “our” or “us” means Labwire, Inc. a Nevada corporation. Our
principal place of business is located at 1514 FM 359, Brookshire, Texas 77423.
Our telephone number is (281) 934-3153.
INFORMATION
REQUIRED IN REGISTRATION STATEMENT
This Form
10 contains certain forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. For this purpose any statements
contained in this Form 10 that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the foregoing, words
such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or
“continue” or comparable terminology are intended to identify forward-looking
statements. These statements by their nature involve substantial risks and
uncertainties, and actual results may differ materially depending on a variety
of factors, many of which are not within Labwire, Inc.’s (the “Company”)
control. These factors include but are not limited to economic conditions
generally and in the industries in which the Company may participate;
competition within the Company’s chosen industry, including competition from
much larger competitors; technological advances and failure by the Company to
successfully develop business relationships.
DEFINITIONS
Certain
abbreviations or acronyms used in the text and notes are defined
below:
Abbreviation or Acronym
|
Term
|
CAP
|
College
of American Pathologists
|
DATIA
|
Drug
and Alcohol Testing Industry Association
|
DEA
|
Drug
Enforcement Administration
|
DHHS
|
U.S.
Department of Health and Human Services
|
DOE
|
Department
of Energy
|
DOD
|
Department
of Defense
|
DOT
|
United
States Department of Transportation
|
EITF
|
FASB’s
Emerging Issues Task Force
|
FACTA
|
Fair
and Accurate Credit Transaction Act of 2003
|
FCRA
|
Fair
Credit Reporting Act of 2001
|
HIPAA
|
Health
Insurance Portability and Accountability Act of 1996
|
HR
|
Human
Resources
|
ISO9000
|
International
Organization for Standardization
|
MRO
|
Medical
Review Officer
|
NIDA
|
National
Institute on Drug Abuse
|
OMB
|
Office
of Management and Budgets
|
SAMHSA
|
Substance
Abuse and Mental Health Services Administration
|
SAPAA
|
Substance
Abuse Program Administrators Association
|
TPA
|
Third
Party Administrator
|
Part
I
ITEM
1. DESCRIPTION OF BUSINESS
Background
of the Company
Labwire
Inc. was incorporated on October 8, 2004 as a Nevada corporation and is
headquartered in Brookshire, Texas. It provides secure and compliant
customized full service drug and alcohol testing and other employment screening
services including billing, customized reports, collection site identification
and management, Medical Review Officer (MRO) services, Supervisor Training,
employee education, client support systems, background checks, physicals,
security services and more to Fortune 500 corporations via the Labwire
Platform. Labwire’s Platform is a proprietary, web-based
application that streamlines the complex regulatory and record management
activities associated with employee screening, delivering accurate timely
results while eliminating service calls and paper trails. The Company’s goal is
to design a comprehensive solution to manage employee screening services that
will be the most efficient and cost-effective platform in the
industry.
Labwire
has two wholly-owned subsidiaries. On October 31, 2004, Workplace Screening
Services, Inc. (“WSS”) was purchased in a stock purchase by issuing 120,000,000
shares of common stock which was valued at $120,000. Along with the
assets of WSS, Labwire assumed $161,232 in short-term debt and $306,128 in
long-term debt. On October 30, 2007, we acquired all of the
outstanding stock of Occupational Testing, Inc. “(Occupational Testing”),
located in Gillette, Wyoming for $120,000 in cash and a note payable for
$480,000 due and payable in quarterly installments of $40,000 each plus accrued
interest at rate of 1% over New York Prime, with the first installment due on
January 31, 2008. Occupational does onsite drug and alcohol testing
primarily for the mining companies in the Gillette, Wyoming
area. Occupational Testing’s revenues for the nine months ended
September 30, 2007 were $614,671 and for the fiscal year ended December 31, 2006
were $698,097. The results of Occupational Testing have been included in the
Company’s financial statements from the date of acquisition.
The
Labwire management team is made up of experienced personnel along with two
senior client service directors. The core management team managed the
sale of over $110 million in drug testing, backgrounds, and related services
before forming Labwire, Inc. and taking advantage of their experience and
expertise, including their in depth knowledge of the required Department of
Transportation (“DOT”) testing regulations (49 CFR, Part 40). As a
result of these efforts, Labwire: (1) enables clients to effectively manage drug
testing programs over the Internet; (2) provides clients with secure and
centralized, collection and analysis of highly confidential data produced by
drug testing; and (3) allows for Web-enabled access to individual test results
and other detailed compliance reports. These revenues account for
approximately 60% of Labwire’s revenues.
Not just
another database, the
Labwire
Platform
was developed by our team of industry leaders to deliver
comprehensive and secure employer information management services over the
Internet. Labwire’s Network Administrator previously authored significant
portions of the federal government’s HIPPA law. At the same time,
Labwire’s goal is to provide its customers with a comprehensive time-saving
workflow automation system.
Our
representatives have also served on national Office of Management and Budget
(OMB) committees working to reduce the amount of paperwork involved in
administering testing programs in the workplace.
Labwire
maintains numerous federal and state certifications and works closely with
strategic partners and key advisors to continually strive for ways to provide a
high level of service and improve our processes and technology
services. See certifications and partners discussions
below.
Services
Labwire
simplifies the complex issues of security and compliance for employee screening
programs in the workplace and significantly reduces administrative time and
costs with a comprehensive full-service program. Labwire has
contracted the development of its proprietary software to control the process
from the periodic selection of employees for random testing to the reporting of
the results back to the clients. Reports of our findings are
generally delivered through a secure Internet connection or through other direct
means. The Company’s network administrator previously worked with the
federal government and participated in the writing of the HIPPA
laws. Following are the services currently provided by
Labwire;
—
|
Secure and Compliant Drug
Testing.
The majority of the Company’s drug testing
clients are required under some federal (49cfr part 40) or state
regulation to perform random periodic drug testing on its
employees. Labwire will select randomly a certain number of
client employees and give the list to the client who will give notice to
the selected employees. These employees will have a certain
length of time to go to a collection facility using certified specimen
collectors as required by the Department of Transportation (Clients have a
list of certified facilities, both primary and backup, that their
employees can use 24 hours a day) and provide a sample for
testing. Our comprehensive nationwide network of collection
sites features on-demand access of a complete database with important
information including certification, performance monitoring, hours of
operation and need for appointments. Labwire contracts with
only SAMHSA certified and accredited laboratories. When
employees present themselves at the collection facility they have to
provide a picture ID and the chain of control over the sample is
begun. The collection facility takes the sample and completes
the paperwork and the sample and paperwork are forwarded to a lab that is
certified by the federal government. The lab results are
reviewed by a medical review officer, certified by national certification
associations, and if the sample tests positive, they will go through a
protocol to determine if it should be classified as substance
abuse. The medical review officer’s report is then forwarded
simultaneously to the client and Labwire. Labwire securely
delivers fast, real-time laboratory test results and reports by Web,
e-mail Adobe Acrobat* pdf file attachments, fax or phone-24 hours a day, 7
days a week.
|
—
|
Custom Statistical Reports and
Data Transfer Services.
Labwire works with new clients
to establish customized software programs and Internet services to issue
reports the way that clients like support custom data interfacing with all
facets of the drug testing program to insure that it is compliant with
federal and state laws and also gives the client and the employees their
proper corporate and individual protections.
|
—
|
Collection Site Management and
Billing Consolidation.
Labwire can manage the myriad of
specimen collections through the thousands of sites in Labwire’s database,
which will free up client resources and relieve them from this daunting
administrative task.
|
—
|
Background
Checks.
Labwire also has the ability to provide its
clients with background check services. Up until recently
this service has been outsourced with Labwire making a commission on the
fee charged by the contracted company. Labwire has recently
acquired access to national data bases and has started to perform its own
background checks. This service generates reports about a
prospective employee’s criminal record, motor vehicle violations, credit
standing and involvement in civil litigation. Labwire’s margins
on this service can be increased by approximately 20%, if done in
house.
|
—
|
Training.
Labwire
provides real-time, online federally mandated supervisor training and
employee education that conforms to all DOT modality requirements in
addition to DOD and DOE. In addition Labwire has just developed
a program for employee training as required under the Fair and Accurate
Credit Transaction Act of 2003 (FACTA), and will begin marketing this
product by September 2008. The education and training system
operates 24/7, is accessible over the Internet, and provides audit
tracking information and annual notification to the clients for ongoing
re-training of supervisors as defined in federal rules. This
program has high margin numbers as do all software driven products and
should very favorably affect net margins.
|
—
|
Security
Services.
Labwire (dba Labwire Security, Inc.) contracts
with American K-9 Bomb Search, Inc., which is one-half owned by Labwire’s
Chairman and Chief Executive Officer, to perform security services.
Labwire Security, Inc. is fully licensed with the State of
Texas. This security model features a web based solution for
reporting and record keeping delivered with a traditional hand on type
product giving client security managers the ability to manage more
locations more securely, effectively, and at lower costs. A
typical weekly consolidated, online report to a client would contain the
numbers and types of vehicles entering, license plates numbers, rail and
marine traffic, incident reports, the times of entering and leaving,
observations of persons and contents, etc. These reports now
allow for the efficient use of resources by security services and client
resources to be managed globally rather than autonomously as now done in
most industries. Labwire is paid a 5% commission for the
K-9 security services that it refers to Labwire Security,
Inc. The commissions received by the Company have been less
than 1% of the Company’s gross revenues.
|
—
|
Data Management and
Transmission.
Labwire has the ability to provide its
clients with secure and compliant, real-time online data management
through an off-site facility. Your entire workflow can be
managed and automated through the use of Labwire’s interfaces. Data
transmission to and from MROs and Collection Sites is
seamless. Labwire has just implemented a customized, completely
integrated reporting and data management solution with a large aerospace
client’s Human Resources (HR) management
system.
|
Market
Opportunity
Virtually
unheard of less than fifteen years ago, drug testing experienced explosive
growth throughout the 1990’s and is now a $5.9 billion industry, according to
estimates from Standard and Poors. Under President
Ronald Reagan, federal employees were required to undergo mandatory drug
testing with a zero tolerance policy, followed in 1988 by Congressional passage
of the Drug-Free Workplace Act, requiring all federal contractors to maintain a
drug free workplace. This was followed by the Omnibus Transportation
Employee Testing Act of 1991, which implemented compulsory and random drug
testing for employees in sensitive transportation positions such as mass transit
operators, commercial truck drivers, and airline pilots. With these
massive federal drug testing programs in place, private employers soon followed
suit. The economic cost of drug and alcohol abuse in the workplace is
tremendous, estimated at between $100 billion and $200 billion each
year. It has been proven that employed drug users are more prone to
accidents, have higher absenteeism rates, higher medical costs, and perform only
at about 67% of their ability. All told, 87% of the nation’s largest
companies test their employees or applicants for drugs, according to a 2001
survey by the American Management Association.
Marketing
and Sales
Labwire
intends to promote itself to large and mid-sized corporations, which conduct
their own internal drug screening programs or currently utilize a
TPA. To this end, Labwire has developed strategic relationships with
a variety of industry organizations, such as the Substance Abuse Program
Administrators Association (SAPAA), the premier trade association for both third
party administrators (TPAs) and large corporate Drug & Alcohol
administrators, and Drug and Alcohol Testing Industry Association (DATIA)
primarily focused on TPAs and collection site operations
nationally.
Recently,
Labwire has begun utilizing alliance agreements with much larger vendors to
promote our products and expand our service offerings and our revenue
base. Our new alliance with USIS Commercial Services, Inc. (“USIS”)
allows us the opportunity to grow our drug and alcohol services through their
existing client base. The USIS agreement was entered into on April 3,
2008 for an initial term of two (2) years. USIS will perform all of
the billings and receive a ten percent (10%) commission on revenue received by
Labwire from USIS referral customers. We are currently exploring
three other alliance opportunities in the areas of employee training, national
and international specimen collection solutions, and additional background and
federally required employment solutions.
Also,
Labwire will conduct direct sales on a highly targeted basis utilizing senior
experienced representatives and outside industry specific consultants to develop
both key vertical customers and channels.
In
addition to strategic relationships and direct sales approaches, Labwire will
conduct its own advertising, public relations and media campaign that will
include print, broadcast, Internet, trade journals, direct mail and all other
applicable news media. Further, we intend to accomplish our public
relations campaign through a variety of means including, but not limited to, the
distribution of press releases and the arranging of press
interviews.
Competition
Testing
for drug use and abuse has evolved at a dramatic rate from a small minority of
companies testing employees for substance abuse in the mid-1980s to the practice
becoming standard in almost all government agencies and large corporate firms in
the 1990s. Legislation requiring the testing of all transportation
industry workers, as well as court decisions upholding the legality of testing
high school students, is making drug testing commonplace in all segments of
society. Overall, the drugs of abuse market was projected to witness
average annual growth of about 4.7% from 2002 to 2007 [Business Communications
Company – July 2002]. Labwire’s principals have provided client
oriented “service philosophy” substance abuse management services for the past
21 years. The Labwire operating platform, which provides modular
delivery systems, procedures compliant with HIPAA protocols standards (unique
within the industry), and live user-friendly access to all clients, all while
adhering to ISO 9000:2000 certification standards specifically for employee
screening (also unique within the industry).
HIPPA
protocols in healthcare are based on the premise that all personally
identifiable information (PII) (social security #, name, address, phone number,
medical records, etc.) should be protected and that every instance of access to
this record by any party be not only noted, but also be available at any time in
a written, reproducible audit trial upon
demand. Labwire’s proprietary software does exactly what he law
requires in HIPPA. We can reproduce every single access to any PII in our entire
database of employee information and deliver a compliant audit trail. We fully
expect our industry to require these same standards in the future and we are
already operating our system to these levels of data security.
ISO 9000
(more formally ISO9001:2000) is an international quality standard that defines
minimum requirements for a company’s Quality Management System (QMS). A
company’s QMS comprises the organization’s policies, procedures and other
internal requirements that ensure customer requirements are met with consistency
resulting in customer satisfaction. Labwire specifically addresses
the concerns generated by the growing “commodity philosophy” (the industry has
moved toward a stance of selling drug testing and backgrounds on a commodity
basis with no real value added mark-ups or margins, basically acknowledging that
all deliverables from any supplier are the same. Labwire now prices based on the
value added by our levels of client service (both personnel and software) and
seeks to attain higher margins than it has in the past when we too had adopted
this commodity approach currently prevalent within the
industry.
With
the recent acquisition of traditional TPA’s by corporate entities not previously
involved in substance abuse management, the need for a return to a service based
philosophy is apparent. Labwire’s experienced staff and compliant
platform are ready to provide its clients with our marketing focus; “Great
Service … Period.”
Labwire
Inc. achieved ISO 9000:2000 certification in April 18, 2005 and has just
celebrated our third successful annual audit and re-certification.
ISO 9000
is a family of
standards for quality management systems. ISO 9000 is maintained by ISO, the
International Organization for Standardization and is administered by
accreditation and certification bodies. Some of the requirements in ISO 9001
(which is one of the standards in the ISO 9000 family)
include
—
|
a
set of procedures that cover all key processes in the
business;
|
—
|
monitoring
processes to ensure they are effective;
|
—
|
keeping
adequate records;
|
—
|
checking
output for defects, with appropriate and corrective action where
necessary;
|
—
|
regularly
reviewing individual processes and the quality system itself for
effectiveness; and
|
—
|
facilitating
continual improvement
|
A company
or organization that has been independently audited and certified to be in
conformance with ISO 9001 may publicly state that it is “ISO 9001 certified” or
“ISO 9001 registered”.
Labwire’s
methods of marketing in this competitive industry consists of traditional
marketing ventures, including direct mail campaigns, selective media
advertising, and participation in targeted conferences and trade
shows. In addition, Labwire is uniquely able to draw upon the
extensive experience of its management to capitalize on personal contacts with
key industry players and deliver a quick response at critical
times. Labwire believes that it has competitive advantages over its
competitors with its Labwire™ Platform, which is a proprietary, web-based
application that streamlines the complex regulatory and record management
activities associated with employee screening, delivering accurate timely
results while eliminating service calls and paper trails. All the data is on one
page and the software is very easy to learn and use. This
comprehensive solution to managing employee screening services is a very t
efficient and cost-effective platform in the industry and the only one, to the
Company’s knowledge, that is currently compliant with HIPPA
regulations.
Labwire
also has joint marketing ventures with key suppliers, such as USIS discussed
above, which allows it access to large companies across the
country.
Principal
Suppliers and Partners
Suppliers
Data
represents a key ingredient in most of our products. In obtaining such data, we
draw upon a wide variety of sources, including governmental agencies, credit
reporting agencies, competitors, customers, third parties which compile public
record information and on-line search services. Many of our suppliers provide
this data in electronic format. We do not anticipate the termination of any
significant relationship with any of our data suppliers. Because we believe we
could acquire necessary data from other sources, we do not believe that the
termination of any supplier relationship would have a material adverse effect on
our financial condition or operating results.
In
connection with our occupational health services, we depend upon services
provided by specimen collection agencies and laboratories. There is significant
competition among suppliers of these services and, consequently, we do not
believe the termination of our relationship with any of these suppliers would
have a material adverse effect on its financial condition or operating
results.
We
obtain some of our data from consumer credit reporting
agencies. Any of these suppliers could stop supplying this data or could
substantially increase their prices. Withholding this data could have a material
adverse effect on our business, financial condition or results of
operations.
We ally
ourselves with the top industry institutions in laboratory analysis (only SAMHSA
certified facilities) and medical review (only licensed physicians certified by
the American Association of Medical Review Officers) in determining the final
results of the drug test, including:
|
—
|
LabCorp -
A major player
in the forensic testing world, LabCorp offers versatility, service and
fully integrated reporting systems to serve our clients. The
Company’s predecessor company, Workplace Screening Services, Inc., entered
into a master service agreement with Laboratory Corporation of America
Holdings on January 22, 2004 for a one year term with automatic annual
extensions unless cancelled by either party. As of the date of
this filing, neither company has given notice of intention to
cancel. The fees for services provided by LabCorp vary by the
type service provided.
|
|
—
|
Substance Abuse Program
Administrators Association -
The Substance Abuse Program
Administrators Association (SAPAA) mission is to establish, promote, and
communicate the highest standards of quality, integrity, and
professionalism in the administration of workplace substance abuse
prevention programs through education, training and the exchange of ideas.
SAPAA’s membership is comprised of TPA’S, In-house administrators, MRO’s,
SAP’s, Collection Sites and Government Agencies. Labwire’s CEO was one of
the 5 founding members of SAPAA. As a founding member, we are very proud
to have had a small part in providing these services to the entire
industry.
|
|
—
|
DATIA -
DATIA’s mission
is to represent the drug and alcohol testing industry in Washington, D.C.
on key legislative and regulatory issues, to expand the workplace drug and
alcohol testing market, to provide members information, resources and
benefits important to their operations and to promote the highest possible
standards for the industry.
|
|
—
|
Quest Diagnostics -
The
largest drug testing laboratory in the US, Quest Diagnostics is
consistently a leader in providing excellent analysis services and
customer service.
|
|
|
—
|
LabOne -
LabOne is a
fully accredited and certified national laboratory that provides
high-quality drug testing and responsive service. Through their
centralized laboratory in Lenexa KS they provide rapid turnaround
time from all parts of the country. LabOne does more DOT testing than any
other laboratory in the US, and is an innovator of new
technologies. They are currently owned by Quest Diagnostics
(see above).
|
|
Dependence
on Major Customers
Labwire
is not dependent on one or a few customers.
Patents,
Trademarks and Licenses
The
Company maintains its Labwire Platform and management systems as proprietary
systems and has a trademark on the name Labwire with the Reg. No. 2,674,091 as
granted on June 24, 2003 under Sections 8 and 15 of the Trademark Act by the
Director of the U.S. Patent and Trademark Office. The Company
controls access to and distribution of its proprietary information.
Governmental
Regulation
Although
generally our services do not require governmental approvals, our business is
subject to various federal and state regulations that may impact our services.
For example, the Federal Fair Credit Reporting Act, Fair and Accurate Credit
Transactions Act, the Drivers Privacy Protection Act, the CAN-SPAM act, federal
and state laws relating to drug testing, federal and state tax credit laws,
state private investigator laws, federal and state laws regulating to
residential-leasing and landlord services, federal and state laws regulating the
hiring process, and various state laws regulating services that include
disclosure of personal information.
Many
state and local laws require certain of strategic partners and employees engaged
in providing our investigative services products to be licensed as private
investigators. Some state and local governments require the same with respect to
our employee screening services.
Historically,
we have been able to comply with existing laws and regulations without incurring
substantial costs or restrictions on our business.
The US
Department of Transportation reserves the right to restrict non-compliance
service providers from performing services for programs covered under 49 CFR
40. Labwire is in full compliance with all such
regulations.
Certifications
Based on
stringent U.S. Department of Transportation standards and protocols, Labwire
services are of the highest standards and fully defensible. We only ally
ourselves with fully licensed providers. Our services conform to
recognized certification and/or compliance, including:
—
|
U.S.
Department of Health and Human Services (DHHS)
|
—
|
Substance
Abuse and Mental Health Services Administration
(SAMHSA)
|
—
|
National
Institute on Drug Abuse (NIDA)
|
—
|
College
of American Pathologists (CAP)
|
—
|
Drug
Enforcement Administration (DEA)
|
—
|
State
Department of Health licensing (where required)
|
—
|
Health
Insurance Portability and Accountability Act of 1996
(HIPAA)
|
—
|
International
Organization for Standardization (ISO9000)
|
—
|
Fair
Credit Reporting Act of 2001 (FCRA)
|
—
|
Fair
and Accurate Credit Transaction Act of 2003
(FACTA)
|
Research
and Development
Labwire
has spend approximately $142,142, $334,461, and $264,621during the
nine months ended September 30, 2008 and the years ended December 31, 2007 and
2006, respectively, on development of its proprietary software to manage
corporate drug testing on line.
Employees
Labwire
has seven full-time employees and 25 service contract individuals available as
used. Labwire has no collective bargaining agreements with its
employees. Labwire believes that its employee relationships are
satisfactory.
Reports
to Security Holders
The
Company recently became subject to the reporting requirements of Section 13 of
the Exchange Act. The Company must now file annual, quarterly and periodic
reports with the Securities and Exchange Commission (“SEC”).
The
public may read and copy any materials filed by the Company with the SEC at the
SEC’s Public Reference Room at 100 F Street, N.E., Washington, DC 20549.
The public may obtain information on the operation of the Public Reference
Room by calling the SEC at 1-800-SEC-0330. The Company is an electronic
filer and the SEC maintains an Internet site that contains reports and other
information regarding the Company that may be viewed
at http://www.sec.gov.
Our
Common Stock
Our
Common Stock is quoted on the over-the-counter Pink Sheets LLC electronic
quotation service under the symbol “LBWR.PK.”
Corporate
Information
Our
principal executive offices are located at 1514 FM 359, Brookshire,
Texas 77423, and our telephone number is (281) 934-3153. Our website
is located at www.labwire.com.
ITEM
1A. RISK FACTORS
An
investment in our Common Stock is highly speculative and is not an appropriate
investment for investors who cannot afford the loss of all or part of their
investment. The risks described below are all of the material risks that we are
currently aware of facing. Additional risks and uncertainties not
presently known to us may also impair our business operations. If any of the
following risks actually occur, our business, financial condition, and results
of operations could be seriously harmed. You could lose all or part
of your investment due to any of these risks.
Our
business is difficult to evaluate because we have a limited operating
history.
Labwire
was incorporated on October 8, 2004, but has only recently begun to generate
meaningful revenue. Because of our limited operating history, we do not have
significant historical financial information on which to base planned revenues
and operating expenses. For the nine months ended September 30, 2008 and the
years ended December 31, 2007, 2006 and 2005, respectively, gross revenues were
approximately $3,168,726, $4,799,631, $3,701,742 and $2,665,364, respectively
and the net income (loss) was $145,367, $345,679, $(500,981) and
$267,876, respectively. We expect to experience fluctuations in
future quarterly and annual operating results that may be caused by many
factors, including:
—
|
our
ability to achieve significant sales for our products and
services;
|
—
|
the
cost of technology, software and other costs associated with production
and distribution;
|
—
|
the
size and rate of growth of the market for Internet products and online
content and services;
|
—
|
the
potential introduction by others of products that are competitive with our
products; and
|
—
|
the
general economic conditions in the United States and
worldwide.
|
In view
of the foregoing, our results of operations and projections of future operating
results are not necessarily meaningful and should not be relied upon as an
indication of future performance.
We
are dependent on information suppliers. If we are unable to manage successfully
our relationships with a number of these suppliers, the quality and availability
of our services may be harmed.
We obtain
some of the data used in our services from third party suppliers and government
entities. If a number of suppliers are no longer able or are unwilling to
provide us with certain data, we may need to find alternative sources. If we are
unable to identify and contract with suitable alternative data suppliers and
integrate these data sources into our service offerings, we could experience
service disruptions, increased costs and reduced quality of our services.
Additionally, if one or more of our suppliers terminates our existing
agreements, there is no assurance that we will obtain new agreements with third
party suppliers on terms favorable to us, if at all. Loss of such access or the
availability of data in the future due to increased governmental regulation or
otherwise could have a material adverse effect on our business, financial
condition or results of operations.
We
may be subject to increased regulation regarding the use of personal
information.
Certain
data and services we provide are subject to regulation by various federal, state
and local regulatory authorities. Compliance with existing federal, state and
local laws and regulations has not had a material adverse effect on our results
of operations or financial condition to date. Nonetheless, federal, state and
local laws and regulations in the United States designed to protect the public
from the misuse of personal information in the marketplace and adverse publicity
or potential litigation concerning the commercial use of such information may
increasingly affect our operations and could result in substantial regulatory
compliance expense, litigation expense and a loss of revenue.
We
face significant security risks related to our electronic transmission of
confidential information.
We rely
on encryption and other technologies to provide system security to effect secure
transmission of confidential or personal information. We may license these
technologies from third parties. There is no assurance that our use of
applications designed for data security, or that of third-party contractors will
effectively counter evolving security risks.
A
security or privacy breach could:
—
|
expose
us to liability;
|
—
|
increase
our expenses relating to resolution of these breaches;
|
—
|
deter
customers from using our services; and
|
—
|
deter
suppliers from doing business with
us.
|
Any
inability to protect the security and privacy of our electronic transactions
could have a material adverse effect on our business, financial condition or
results of operations.
Labwire
may be adversely affected by recent high-profile events involving data theft at
a number of information services companies.
Several
information services companies that are competitors of Labwire have recently
been involved in high-profile events involving data theft. These incidents or
similar data theft incidents in the future could impact Labwire. In
particular, these events could result in increased legal and regulatory scrutiny
of the industry in general and specific information services companies in
particular and changes in federal, state and local laws and regulations in the
United States designed to protect the public from the misuse of personal
information in the marketplace. Changes in the laws and adverse publicity or
potential litigation concerning the commercial use of such information may
affect Labwire’s operations and could result in substantial regulatory
compliance expense, litigation expense and a loss of revenue.
We
could face liability based on the nature of our services and the content of the
materials provided which may not be covered by insurance.
We may
face potential liability from individuals, government agencies or businesses for
defamation, invasion of privacy, negligence, copyright, patent or trademark
infringement and other claims based on the nature and content of the materials
that appear or are used in our products or services. Insurance may not be
available to cover claims of these types or may not be adequate to cover us for
all risks to which we are exposed. Any imposition of liability, particularly
liability that is not covered by insurance or is in excess of our insurance
coverage, could have a material adverse effect on our business, financial
condition or results of operations.
We
may not be able to pursue our acquisition strategy.
Our
strategy is to grow through acquisitions. We may not be able to identify
suitable acquisition candidates, obtain the capital necessary to pursue our
acquisition strategy or complete acquisitions on satisfactory terms. A number of
our competitors also have adopted the strategy of expanding and diversifying
through acquisitions. We likely will experience competition in our effort to
execute on our acquisition strategy, and we expect the level of competition to
increase. As a result, we may be unable to continue to make acquisitions or may
be forced to pay more for the companies we are able to acquire.
The
integration of companies we acquire may be difficult and may result in a failure
to realize some of the anticipated potential benefits of our
acquisitions.
When we
acquire companies or businesses, we may not be able to integrate or manage these
businesses so as to produce returns that justify the investment. Any difficulty
in successfully integrating or managing the operations of the businesses could
have a material adverse effect on our business, financial condition, results of
operations or liquidity, and could lead to a failure to realize any anticipated
synergies. Our management also will be required to dedicate substantial time and
effort to the integration of our acquisitions. These efforts could divert
management’s focus and resources from other strategic opportunities and
operational matters. The exact amount of funds raised, if any, will
determine how aggressively we can grow and what additional projects we will be
able to undertake. No assurance can be given that we will be able to raise
additional capital, when needed or at all, or that such capital, if available,
will be on terms acceptable to us. If we are not able to raise additional
capital, the growth of our business could suffer.
Our success will be limited if we are
unable to attract, retain and motivate highly skilled
personnel.
Our
future success also will depend on our ability to attract, retain and motivate
highly skilled engineering, management, sales and other key personnel.
Competition for such personnel is, at times, intense in the Internet industry,
and we may be unable to successfully attract, integrate or retain sufficiently
qualified personnel. In addition, our ability to generate revenues relates
directly to our personnel in terms of both numbers and expertise of the
personnel we have available to work on the projects. Moreover, competition for
qualified employees may require us to increase our cash or equity compensation,
which may have an adverse effect on earnings.
Any
system failure or slow down could significantly harm our reputation and damage
our business.
System
failures would harm our reputation and reduce our attractiveness to clients. Our
ability to attract potential clients will depend significantly on the
performance of our network infrastructure. In addition, a key element of our
strategy is to perform services for clients to increase their usage of our
services. Usage of our online services could strain the capacity of our
infrastructure, resulting in a slowing or outage of services and reduced traffic
to clients’ web sites. We may be unable to improve our technical infrastructure
in relation to increased usage of our services. In addition, the users of the
systems we deploy for our clients depend on Internet service providers, online
service providers and other web site operators for access to our web sites. Many
of these providers and operators have also experienced significant outages in
the past, and they could experience outages, delays and other difficulties due
to system failures unrelated to our systems. We may provide some of our clients
with a service level agreement guarantee based on the size of the client and the
amount of the business generated with our Company. This guarantee could result
in financial penalties to us that could have a material adverse effect on our
business, financial condition and operating results.
We
compete in a highly competitive market and many of our competitors have greater
financial resources and established relationships with major corporate
customers.
The
information industry in which we operate is highly competitive, and is expected
to remain highly competitive. In each of the markets served, we compete on the
basis of price, quality, customer service and product and service selection. Our
competitive position in various market segments depends upon the relative
strength of competitors in the segment and the resources devoted to competing in
that segment. Due to their size, certain competitors may be able to allocate
greater resources to a particular market segment than we can. As a result, these
competitors may be in a better position to anticipate and respond to changing
customer preferences, emerging technologies and market trends. In addition, new
competitors and alliances may emerge to take market share away. We may be unable
to maintain or strengthen our competitive position in our market segments,
especially against larger competitors. We any incur additional costs to upgrade
systems in order to compete. If we fail to successfully compete, our business,
financial position and results of operations may be adversely
affected.
Our
business could suffer if we are unable to protect our intellectual property
rights or are liable for infringing the intellectual property rights of
others.
We regard
our
Labwire
software
platform as critical to our success, and we rely upon and confidentiality and
license agreements with our employees, strategic partners, and others to protect
our proprietary rights, which can have only limited effectiveness.
Further,
we may be subject to claims in the ordinary course of our business, including
claims of alleged infringement of the trademarks, copyrights and other
intellectual property rights of third parties by us and our
licensees.
Other
parties may assert claims of infringement of intellectual property or other
proprietary rights against us. These claims, even if without merit, could
require us to expend significant financial and managerial resources.
Furthermore, if claims like this were successful, we might be required to change
our trademarks, alter our content or pay financial damages, any of which could
substantially increase our operating expenses. We also may be required to obtain
licenses from others to refine, develop, market and deliver new services. We may
be unable to obtain any needed license on commercially reasonable terms or at
all, and rights granted under any licenses may not be valid and enforceable. In
the future we could be subject to legal proceedings and claims from time to time
in the ordinary course of our business, including claims of alleged infringement
of trademarks and other intellectual property rights of third parties by us and
our licensees. Any such claims could have a material adverse effect on our
business, financial condition and operating results.
We
face potential liability related to the privacy of health information we
obtain.
Most
health care providers, from which we may obtain patient information, are subject
to privacy regulations promulgated under the Health Insurance Portability and
Accountability Act of 1996, or HIPAA. Although we are not directly regulated by
HIPAA, we could face substantial criminal penalties if we knowingly receive
individually identifiable health information from a health care provider that
has not satisfied HIPAA’s disclosure standards. Further, we may face civil
liability if our HIPAA compliant system fails to satisfy its disclosure
standards. Claims that we have violated individuals’ privacy rights or breached
our contractual obligations, even if we are not found liable, could be expensive
and time-consuming to defend and could result in adverse publicity that could
harm our business.
Our
business will not succeed if we are unable to keep pace with rapid technological
changes.
We use
the
Labwire P
latform
technology designed
by our Company and other information technology to better serve our clients and
reduce costs. These technologies likely will change and may become obsolete as
new technologies develop. Our future success will depend upon our ability to
remain current with the rapid changes in the technologies used in our business,
to learn quickly to use new technologies as they emerge and to develop new
technology-based solutions as appropriate. If we are unable to do this, we could
be at a competitive disadvantage. Our competitors may gain exclusive access to
improved technology, which also could put us at a competitive disadvantage. If
we cannot adapt to these changes, our business, financial condition or results
of operations may be materially affected in an adverse manner.
If we
suffer system failures or overloading of computer systems, our business and
prospects could be harmed. The success of our online offerings is highly
dependent on the efficient and uninterrupted operation of our computer and
communications hardware systems. Fire, floods, earthquakes, power fluctuations,
telecommunications failures, hardware “crashes,” software failures caused by
“bugs” or other causes, and similar events could damage or cause interruptions
in our systems. Computer viruses, electronic break-ins or other similar
disruptive problems could also adversely affect our websites. If our systems, or
the systems of any of the websites on which we advertise or with which we have
material marketing agreements, are affected by any of these occurrences, our
business, results of operations and financial condition could be materially and
adversely affected.
We
presently carry insurance policies that cover losses that may occur due to any
failures or interruptions in our systems. We do have a secondary “off-site”
system and a formal disaster recovery plan. In addition, our users depend on
Internet service providers and other Internet site operators for access to our
websites. Many Internet service providers have experienced significant outages
in the past, and could experience outages, delays and other difficulties due to
system failures unrelated to our systems. If we experience any of these
problems, and if our insurance did not cover the costs of such occurrences, our
business, results of operations and financial condition could be materially and
adversely affected.
Disruptions
to the business of our strategic partners could affect our
business.
The
success of our business depends on the continued uninterrupted use of the
technology supplied to us by our strategic partners. If the business operations
of any of our strategic partners are materially disrupted, our operations may be
disrupted and, as a result, our financial condition could be materially and
adversely affected.
We
are dependent on our management and employees.
We are
dependent on the services of our executive officers and key employees. As of
this date, we have 7 fulltime employees, 3 of whom are members of
management. We do not have an employment agreement with any member of
management. Moreover, no member of management has entered into a
covenant not to compete agreement with us. As result, each member of
management may discontinue providing his services to us at any time and for any
reason, and even thereafter commence competition with us. We currently do not
maintain key-man life insurance policies on key executive officers of the
Company. There can be no assurance that we can obtain executives of
comparable expertise and commitment in the event of death, or that our business
would not suffer material adverse effects as the result of the death, disability
or voluntary departure of any such executive officer. Further, the loss of the
services of any one or more of these employees could have a materially adverse
effect on our business and our financial condition. In addition, we
will also need to attract and retain other highly skilled technical and
managerial personnel for whom competition is intense. If we are unable to do so,
our business, results of operations and financial condition could be materially
adversely affected.
We
may issue additional shares that could dilute your potential ownership interest
and limit the ability of a third party to obtain voting control.
Some
events over which investors in the Company have no control could result in the
issuance of additional shares of our Common Stock or issuances of preferred
stock (of which none is currently outstanding), which would dilute your
ownership percentage in Labwire, Inc. We may issue additional shares
of Common Stock:
—
|
to
raise additional capital or finance acquisitions;
|
—
|
upon
the exercise or conversion of outstanding warrants or convertible
notes;
|
—
|
in
lieu of cash payment of interest on our outstanding convertible
subordinated notes; or
|
—
|
to
vendors in exchange for products or
services.
|
We
will incur increased costs as a result of becoming a reporting
company.
In April
2008, we became a Securities and Exchange Commission (“SEC”) reporting company.
Prior to this time, we have not filed reports with the SEC and had no history
operating as a reporting company. In addition, the Sarbanes-Oxley Act of 2002,
as well as a variety of related rules implemented by the SEC, have required
changes in corporate governance practices and generally increased the disclosure
requirements of public companies. For example, as a result of becoming a
reporting company, we will be required to file periodic and current reports,
proxy statements and other information with the SEC and we must adopt policies
regarding disclosure controls and procedures and regularly evaluate those
controls and procedures. As a reporting company, we will incur significant
additional legal, accounting and other expenses in connection with our public
disclosure and other obligations. Management will be engaged in assisting
executive officers, directors and, to a more limited extent, stockholders, with
matters related to insider trading and beneficial ownership reporting. Although
not presently applicable to us, in the future we will be required to establish,
evaluate and report on our internal control over financial reporting and to have
our registered independent public accounting firm issue an attestation as to
such reports.
We have
incurred, and expect to continue to incur, increased general and administrative
expenses as a reporting company. We also believe that compliance with the myriad
rules and regulations applicable to reporting companies and related compliance
issues will divert time and attention of management away from operating and
growing our business.
Being a
public company also increases the risk of exposure to class action stockholder
lawsuits and SEC enforcement actions, and increases the expense to obtain
appropriate director and officer liability insurance on acceptable or even
reduced policy limits and coverage. As a result, we may find it more difficult
to attract and retain qualified persons to serve on our board of directors or as
executive officers.
Our
Common Stock is subject to the SEC’s penny stock rules, and, therefore,
broker-dealers may experience difficulty in completing customer transactions and
trading activity in our securities may be adversely affected.
A penny
stock is generally defined under the Securities Exchange Act of 1934, as amended
(“Exchange Act”) as any equity security other than a security that: (i) is an
national market system stock listed on a “grandfathered” national securities
exchange, (ii) is a national market system stock listed on a national securities
exchange or an automated quotation system sponsored by a registered national
securities association that satisfies certain minimum quantitative listing
standards, (iii) has a transaction price of five dollars or more, or (iv) is a
security whose issuer has met certain net tangible assets or average revenues,
among other exemptions. Our Common Stock is not currently traded on a national
securities exchange or quotation system sponsored by a national securities
exchange and our price as reported on the Pink Sheets, LLC, is currently less
than five dollars.
In
accordance with the rules governing penny stocks, broker-dealers participating
in transactions in low-priced securities must first deliver a risk disclosure
document that describes the risks associated with such stocks, the
broker-dealer’s duties in selling the stock, the customer’s rights and remedies
and certain market and other information. Furthermore, the broker-dealer must
make a suitability determination approving the customer for low-priced stock
transactions based on the customer’s financial situation, investment experience
and objectives. Broker-dealers must also disclose these restrictions in writing
to the customer, obtain specific written consent from the customer and provide
monthly account statements to the customer.
The
effect of these restrictions may decrease the willingness of broker-dealers to
make a market in our Common Stock, decrease liquidity of our Common Stock and
increase transaction costs for sales and purchases of our Common Stock as
compared to other securities. Broker-dealers may find it difficult to effectuate
customer transactions in our Common Stock and trading activity in our Common
Stock may be adversely affected. As a result, the market price of our Common
Stock may be depressed and stockholders may find it more difficult to sell their
shares of Common Stock.
If
we fail to maintain an effective system of internal control over financial
reporting and disclosure controls and procedures, we may be unable to accurately
report our financial results and comply with the reporting requirements under
the Exchange Act.
Pursuant
to Section 404 of the Sarbanes-Oxley Act of 2002 (“Section 404”), we
will be required, beginning with our annual report on Form 10-K for the
fiscal year ending December 31, 2009, to include in our annual reports on
Form 10-K, our management’s report on internal control over financial
reporting and the registered public accounting firm’s attestation report on our
management’s assessment of our internal control over financial reporting. We
intend to prepare an internal plan of action for compliance with the
requirements of Section 404. As a result, we cannot guarantee that we will
not have any “significant deficiencies” or “material weaknesses” within our
processes. Compliance with the requirements of Section 404 is expected to
be expensive and time-consuming. If we fail to complete this evaluation in a
timely manner, we could be subject to regulatory scrutiny and a loss of public
confidence in our internal control over financial reporting. In addition, any
failure to establish an effective system of disclosure controls and procedures
could cause our current and potential stockholders and customers to lose
confidence in our financial reporting and disclosure required under the Exchange
Act, which could adversely affect our business.
We
are controlled by our principal
stockholders and management, which will limit other stockholders’ ability to
influence our operations and may affect the likelihood that other stockholders
will receive a premium for your securities through a change in
control.
Our
executive officers, directors and principal stockholders and their affiliates
own approximately 85% of the outstanding shares of Common Stock as of the date
of this Registration Statement. These parties effectively control the Company
and direct its affairs and have significant influence in the election of
directors and approval of significant corporate transactions. The interests of
these stockholders may conflict with those of other stockholders. This
concentration of ownership may also delay, defer or prevent a change in control
of us and some transactions may be more difficult or impossible without the
support of these stockholders.
Our
Common Stock has a very limited trading market.
Our
Common Stock is traded on the over-the-counter Pink Sheets LLC electronic
quotation service, an inter-dealer quotation system that provides significantly
less liquidity than the NASDAQ stock market or any other national securities
exchange. In addition, trading in our Common Stock has historically been
extremely limited. This limited trading adversely affects the liquidity of our
Common Stock, not only in terms of the number of shares that can be bought and
sold at a given price, but also through delays in the timing of transactions and
reduction in security analysts’ and the media’s coverage of us. As a result,
there could be a larger spread between the bid and ask prices of our Common
Stock and you may not be able to sell shares of our Common Stock when or at
prices you desire.
We
do not intend to pay dividends.
We
currently intend to retain any future earnings to fund growth and, therefore, do
not expect to pay any dividends to our stockholders in the near
future.
Our
bylaws provide for our indemnification of our officers and
directors.
Our
bylaws require that we indemnify and hold harmless our officers and directors,
to the fullest extent permitted by law, from certain claims, liabilities and
expenses under certain circumstances and subject to certain limitations and the
provisions of Nevada law. Under Nevada law, a corporation may indemnify any
person who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (other than an action by or in the
right of the corporation) by reason of the fact that he is or was a director,
officer, employee or agent of the corporation, against expenses, attorneys fees,
judgments, fines and amounts paid in settlement, actually and reasonably
incurred by him in connection with an action, suit or proceeding if the person
acted in good faith and in a manner reasonably believed to be in or not opposed
to the best interests of the corporation.
ITEM
2. FINANCIAL INFORMATION
The
following information should be read in conjunction with the financial
statements of Labwire, Inc. and the notes thereto appearing elsewhere in this
registration statement. Statements in this Item and elsewhere in this
registration statement that are not statements of historical or current fact
constitute “forward looking statements.” All statements contained in
this registration statement that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,”
“plan,” “will,” and similar expressions are generally intended to identify
forward-looking statements. Most of the statements made herein are
forward-looking.
Our
business and results of operations are affected by a wide variety of factors,
many of which are discussed under the heading “Risk Factors” and elsewhere in
this registration statement, which could materially and adversely affect our
actual results and us. Because of these factors, we may experience
material fluctuations in future operating results on a quarterly or annual
basis, which could materially and adversely affect our business, financial
condition, operating results and stock price.
Although
we believe that the expectations reflected in the forward-looking statements are
reasonable, we do not guarantee future results, levels of activity, performance
or achievements. Except as required by law, we are under no duty to update or
revise any of the forward-looking statements, whether because of new
information, future events or otherwise, after the date of this registration
statement.
Company
Overview
Labwire,
Inc. was incorporated in 2004 as a Nevada corporation and is headquartered in
Brookshire, Texas, close to metropolitan Houston. We are a leading
provider of certain third party administrator (“TPA”) services. As a
provider of TPA services, we administer certain programs for our clients,
allowing them to outsource matters that they would prefer not to undertake
in-house on their own. We act as a TPA with respect to the following
three types of services:
1.
|
Drug
testing and other employee screening – In connection with the provision of
these services, we supervise specimen collection and test processing by
federally certified labs. We also provide a medical review
officer, who interprets the results of the testing. Moreover,
unrelated to drug testing, we supervise background screening and on-site
testing, which includes audio and vision testing, general employee
physicals, and metal testing of employees engaged in operations such as
mining.
|
2.
|
Employee
training and online certification –
In connection with
the provision of these services, we have developed training and education
programs to enable clients to comply with certain government
regulations. Currently, some of these programs deal with
Department of Transportation regulations, while others deal with Federal
Trade Commission regulations. We plan to broaden our offering
of these programs in the future, as we are
able.
|
3.
|
Security –
In connection with the provision of these services, we provide K-9 dog
teams that search for bombs or drugs, supervise on-site physical security
teams, and undertake some surveillance
work.
|
We
operate through two wholly-owned subsidiaries, Workplace Screening Services,
Inc. and Occupational Testing, Inc. We have developed the Labwire™
Platform, an innovative, proprietary Web-based application that (a) streamlines
the complex regulatory and record management activities associated with our drug
testing, and (b) offers our employee training and online certification
programs. This application figures prominently into our business
strategy. Moreover, our management team has extensive experience in
our business and industry.
We became
a reporting company with the U.S. Securities and Exchange Commission (the
“Commission”) when our General Form for Registration of Securities on Form 10
became effective on or about April 14, 2008.
There can
be no assurance that we will be successful in our business. Our
business involves numerous risks, the principal ones of which are described in
the section captioned “ITEM 1A. RISK FACTORS.”
The
following discussion and analysis of our financial condition and results of
operations should be read in conjunction with our consolidated financial
statements and related notes included elsewhere in this Report. In
addition to historical information, the discussion in this Report contains
forward-looking statements that involve risks and
uncertainties. Actual results could differ materially from those
anticipated by these forward-looking statements due to factors including, but
not limited to, those factors set forth elsewhere in this Report and in the
section captioned “ITEM 1A. RISK FACTORS.”
Results
of Operations
Nine
months ended September 30, 2008 compared with nine months ended September 30,
2007
The
following table sets forth certain operating information (unaudited) regarding
the Company for the nine month periods ended September 30, 2008 and
2007:
|
Nine
Months Ended
September
30
|
|
2008
|
2007
|
|
(unaudited)
|
(unaudited)
|
|
|
|
Revenues
|
$ 3,168,726
|
$ 3,529,956
|
Cost
of operations
|
1,707,178
|
2,285,302
|
Gross
Profit
|
1,461,548
|
1,244,654
|
General
and administrative expenses
|
1,221,616
|
849,246
|
Net
income
|
$ 145,367
|
$ 338,125
|
|
|
|
Net
income per share
|
$ 0.00
|
$ 0.00
|
Revenues
Revenues
for the nine-month periods ended September 30, 2008 and 2007 were $3,168,726 and
$3,529,956, respectively. Our revenues decreased principally because
the revenues in 2007 included approximately $208,000 in collections on accounts
previously written off and the Company’s training and education contracts
amounting to approximately $400,000 per quarter expired and are not expected to
be renewed until the second quarter of 2009.
Operating
Expenses
Operating
expenses for the nine-month periods ended September 30, 2008 and 2007 were
$1,221,616 and $849,246, respectively. The $372,370 increase was
primarily due an increase of $230,407 in the Company’s payroll expense primarily
as the result of the addition of the OTI operation in Wyoming, a $24,566
increase in contract labor, a $18,956 increase in professional fees, a $24,871
increase in office supplies, a $30,586 increase in the amortization of
capitalized software development and a $18,630 increase in postage and delivery
expenses.
Operating
Income
Our
operating income for the nine-month period ended September 30, 2008 was $239,932
compared to an operating income of $395,408 for the nine-month period ended
September 30, 2007. The $155,476 decrease in operating income from
the 2008 period to the 2007 period is attributed primarily to the approximately
$208,000 in collections on accounts previously written off and collected during
the nine-months ended September 30, 2007. The Company would have
experienced an approximately $75,000 increase in 2008 when the 2007 number is
adjusted for the $208,000 and this increase would be attributable to the
additional income from the OTI subsidiary.
Year
Ended December 31, 2007 Compared to Year Ended December 31, 2006
The
following table sets forth certain comparative operating information regarding
Labwire:
|
Year
Ended December 31,
|
|
2007
|
2006
|
Sales
|
$
4,557,699
|
$
3,701,742
|
Cost
of Goods Sold, net of depreciation
|
3,094,530
|
2,552,686
|
Gross
Profit
|
1463,169
|
1,149,056
|
Operating
Expenses:
|
|
|
Selling,
general and administrative
|
604,545
|
1,101,325
|
Depreciation
|
23,580
|
16,022
|
Total
Operating Expenses
|
1,284,911
|
1,617,937
|
Income
(Loss) from Operations
|
178,258
|
(468,881)
|
Net
(loss)
|
103,747
|
(500,981)
|
|
|
|
Basic
Earnings (loss) per Share
|
$
.0007
|
$
(.0036)
|
Revenues
Total
revenues for fiscal years 2007 and 2006 were $4,557,699 and $3,701,742,
respectively, as the operations of Labwire grew 23% as the result of increased
test procedures and training and education courses administered by the
Company.
Selling,
General and Administrative Expenses
General
and administrative expenses decreased from $1,010,325 in fiscal year 2006 to
$604,545 in the fiscal year ended December 31, 2007. This decrease is
principally attributable to the Company’s ability to outsource drug testing
services and reduce payroll and related general and administrative services
relative to the increase in revenues.
Results
of Operations
Our
operating income for the year ended December 31, 2007 was $178,258 compared to
an operating loss of ($468,881) for the year ended December 31,
2006. The $647,139 increase in operating income from the 2006 period
to the 2007 period is attributed to a $549,733 increase in gross profit
resulting from increase in test procedures performed and a decrease of
$349,338 in operating expenses, again reflecting the Company’s ability to
increase its monthly drug testing services revenues and outsource these drug
testing services to reduce payroll and general and administrative
services.
The
Company had a net income of $103,747 for the year ended December 31, 2007
compared to a net loss of $(500,981) for the year ended December 31,
2006. This increase of 604,728 is principally attributable to
the Company’s ability to increase its monthly drug testing services revenues and
outsource these drug testing services to reduce payroll and general and
administrative services.
Liquidity and Capital
Resources
From
inception until the third quarter of 2007, our primary sources of capital were
proceeds from private placements of our common stock, loans from shareholders
and bank lines of credit. We began to experience positive cash flow
in the third quarter of 2007, which has allowed us to provide our own operating
capital for our operations and reduced the need to access outside capital
sources to support current operations. We currently require
approximately $130,000 per month to fund our recurring operations. This amount
would likely increase if we expand our sales and marketing efforts and continue
to develop new products and services as are our plans. Our cash needs
are primarily attributable to funding sales and marketing efforts, strengthening
technical and helpdesk support, expanding our development capabilities, and
building administrative infrastructure, including costs and professional fees
associated with being a public company. We intend to meet our
immediate capital needs from cash flow provided from operations. We
believe that we have sufficient funding to cover our cash needs for the next 12
months, although there can be no assurance in this regard.
As of
September 30, 2008, we had cash and cash equivalents of $77,485. The
largest uses of our funds are funding general and administrative expenses and
salaries and related expenses. As of September 30, 2008, we had total
current liabilities of $961,488 and total current assets of $1,125,094, with our
current assets exceeding our current liabilities by $163,606.
Net cash
used by operating activities was $458,461 for the nine months ended September
30, 2008, compared to net cash provided by operating activities of $73,154 for
the nine months ended September 30, 2007. The increase in cash used
by operating activities in comparing the nine months ended September 30, 2008 to
the nine months ended September 30, 2007 can be attributed primarily to 2008
having a net loss of $96,565 compared to 2007 having a net income of
$338,125.
We have
two outstanding loans with Frost National Bank (“Frost”). On February
13, 2008, we established a $300,000 revolving line of credit with Frost that
originally scheduled to mature on February 13, 2008. However, on or
about March 4, 2008, we converted this revolving line of credit into a term note
with an original principal amount of approximately $241,932. This
term note is due and payable in 36 level monthly payments. The
interest rate on the outstanding balance of this term note is a floating rate of
prime plus 1%. This term note is secured by our accounts
receivable. The outstanding principal balance on this term note as of
September 30, 2008 was $204,143.
On or
about March 4, 2008, we established a new $300,000 revolving line of credit with
Frost that is scheduled to mature on February 13, 2010, at which time a balloon
payment comprised of all outstanding principal and accrued interest must be
paid. The interest rate on the outstanding balance of the revolving
line of credit is a floating rate of prime plus 1%, and a payment of all accrued
interest is due monthly throughout the term of the line of
credit. This revolving line of credit is secured by our accounts
receivable. The outstanding principal balance on this line of credit
as of September 30, 2208 was $300,000.
As of
September 30, 2008, we also had a $434,355 promissory note outstanding and
payable at a floating rate of interest of prime plus 1%. The note is
related to the purchase of Occupational Testing, Inc.
As of
September 30, 2008, we also had a $300,000 promissory note outstanding and
payable at an interest rate of 4% per annum and payable on December 31,
2008.
The
long-term success of our operations depends on our ability to (1) increase the
deployment of our Labwire™ Platform, (2) significantly increase our services
revenue through the deployment of the Labwire™ Platform, both through increases
in drug and alcohol testing, and usage of employee training and online
certification programs, and (3) increase our revenues from K-9 security
services. We intend to raise additional capital through an offering
of our Common Stock or other securities to provide additional working capital to
fund the expansion of operations through acquisitions and the addition of new
clients through marketing efforts and joint ventures with other service
organizations. We intend to seek up to approximately $2.0 million in
capital in the near future in this connection. The exact amount of
funds raised, if any, will determine how aggressively we can grow and what
additional projects we will be able to undertake. Assuming that we
are able to raise the $2.0 million in new capital, we currently anticipate
spending approximately $250,000 in marketing and sales in its efforts to sign
new clients and seek additional alliances. No assurance can be given
that we will be able to raise additional capital, when needed or at all, or that
such capital, if available, will be on terms acceptable to us. If
adequate funds are not available on acceptable terms, our business, results of
operations and financial condition could be materially adversely
affected. In a worst-case scenario, we would have to scale back or
cease operations, and we might not be able to remain a viable
entity.
In
addition common stock may also be issued for conversion or settlement of debt
and/or payables for equity, future obligations which may be satisfied by the
issuance of common shares, and other transactions and agreements which may in
the future result in the issuance of additional common shares. The common shares
that we may issue in the future could significantly increase the number of
shares outstanding and could be extremely dilutive.
Contractual
Obligations
Future
payments due on our contractual obligations as of September 30, 2008 are as
follows:
|
Total
|
2008
|
2009-2010
|
2010-2012
|
Thereafter
|
Operating
lease
|
$
22,600
|
$
22,600
|
$
-
|
$
-
|
$
-
|
Notes
payable
|
882,440
|
376,950
|
235,552
|
235,552
|
34,386
|
Line
of credit
|
300,000
|
-
|
300,000
|
-
|
-
|
Total
|
$
1,205,040
|
$
399,550
|
$
535,552
|
$
235,552
|
$
34,386
|
Critical
Accounting Policies and Estimates
Our
discussion of our financial condition and results of operations is based on the
information reported in our financial statements. The preparation of our
financial statements requires us to make assumptions and estimates that affect
the reported amounts of assets, liabilities, revenues and expenses as well as
the disclosure of contingent assets and liabilities as of the date of our
financial statements. We base our assumptions and estimates on historical
experience and other sources that we believe to be reasonable at the time.
Actual results may vary from our estimates due to changes in circumstances,
weather, politics, global economics, mechanical problems, general business
conditions and other factors. Our significant accounting policies are detailed
in Note 1 to our financial statements included in this Amendment on Form
10. We have outlined below certain of these policies that have
particular importance to the reporting of our financial condition and results of
operations and that require the application of significant judgment by our
management.
Impairment
of Long-Lived Assets
We review
long-lived assets, such as property and equipment, and purchased intangibles
subject to amortization, for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable, in accordance with Statement of financial Accounting Standards
(“SFAS”) No. 144, Accounting for the Impairment for Disposal of Long-Lived
Assets. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset. If the carrying amount of an asset
exceeds its estimated future cash flows, impairment charge is recognized by the
amount of the asset exceeds the fair value of the asset.
Fair
Value of Financial Instruments
Management
believes that the carrying amounts of our financial instruments, including cash
and cash equivalents, accounts receivable, accounts payable, and accrued
liabilities approximate fair value due to the short-term nature of these
instruments. The carrying amount of our long-term debt also approximates fair
value, based on market quote values (where applicable) or discounted cash flow
analyses.
Income
Taxes
We
account for income taxes under SFAS No. 109, which requires the asset and
liability approach to accounting for income taxes. Under this method, deferred
tax assets and liabilities are measured based on differences between financial
reporting and tax bases of assets and liabilities measured using enacted tax
rates and laws that are expected to be in effect when differences are expected
to reverse. Valuation allowances are established when it is necessary to reduce
deferred income tax assets to the amount, if any, expected to be realized in
future years.
Net
earnings (loss) per share
Basic and
diluted net loss per share information is presented under the requirements of
SFAS No. 128, Earnings per Share. Basic net loss per share is computed by
dividing net loss by the weighted average number of shares of Common Stock
outstanding for the period, less shares subject to repurchase. Diluted net loss
per share reflects the potential dilution of securities by adding other common
stock equivalents, including stock options, shares subject to repurchase,
warrants and convertible notes in the weighted-average number of common shares
outstanding for a period, if dilutive. All potentially dilutive securities have
been excluded from the computation, as their effect is
anti-dilutive.
Use
of Estimates
The
preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets, liabilities and disclosures at the date
of the financial statements and the reported amounts of revenue and expenses
during the reporting periods. Actual results could differ from those
estimates.
Revenue
Recognition
We have
three main sources of revenue: drug testing and related services, training and
online certification, and security services provided by an allied
company. Drug testing: we fulfill orders for drug testing services,
wherein we are responsible for the performance and data maintenance related to
employee drug testing for its clients. We do not perform the drug
tests, but we fulfill the order through our network of third party labs and
other drug testing facilities. Revenue is recognized when the drug
testing has been completed by the lab and the customer has been invoiced for the
services. We have low bad debt levels because our policy is to deal
with large well-positioned firms that pay monthly. Because we track these
company’s activities daily, we are constantly aware of our position and
therefore can demand and receive timely payments as we provide on-going
compliance services. Pursuant to EITF 99-19, we are responsible for fulfilling a
customer’s order, including whether the service is acceptable and therefore
bears the risks and rewards of principal. As such, we have elected to
record the gross amounts of the contracts. Our service agreements
rarely include multiple parts that would have a material impact on the
recognition of revenue. As such, we have created our revenue
recognition policies pursuant to EITF 00-21.
Online
training and certification: the Company has designed online testing for various
certifications which client employees must attain for their
employment. The employee takes the certification examinations online
and the client is automatically tagged for billing, which coincides with
performance of services.
Security
services provided by us through an allied company: the process is handled in
similar fashion to that described above for drug testing.
Allowance
for Uncollectible Receivables
The
allowance for all probable uncollectible receivables is based on a
combination of historical data, cash payment trends, specific customer issues,
write-off trends, general economic conditions and other factors. These factors
are continuously monitored by management to arrive at an estimate for the amount
of accounts receivable that may ultimately be uncollectible. In circumstances
where we are aware of a specific customer’s inability to meet its financial
obligations, we record a specific allowance for bad debts against amounts due to
reduce the net recognized receivable to the amount it reasonably believes will
be collected. This analysis requires making significant estimates, and changes
in facts and circumstances could result in material changes in the allowance for
uncollectible receivables.
Software
Development Costs
During
the period, we began developing a software platform for certain exclusively
internal purposes. We follow the guidance set forth in Statement of
Position 98-1,
Accounting for
the Cost of Computer Software Developed or Obtained for Internal Use
(SOP 98-1), in accounting for costs incurred in the development of
its on-demand application suite. SOP 98-1 requires companies to capitalize
qualifying computer software costs that are incurred during the application
development stage and amortize them over the software’s estimated useful
life.
We
capitalize costs associated with developing software for internal use, which
costs primarily include salaries of developers. Direct costs incurred
in the development of software are capitalized once the preliminary project
stage is completed, management has committed to funding the project and
completion, and use of the software for its intended purpose are
probable. We cease capitalization of development costs once the
software has been substantially completed at the date of conversion and is ready
for its intended use. The estimation of useful lives requires a significant
amount of judgment related to matters, specifically, future changes in
technology. We believe no events or circumstances warrant revised estimates of
useful lives of the software.
Purchase
Accounting
We
completed acquisitions in 2004 and the fourth quarter of 2007. The purchase
method of accounting requires companies to assign values to assets and
liabilities acquired based upon their fair values. In most instances, there is
not a readily defined or listed market price for individual assets and
liabilities acquired in connection with a business, including intangible assets.
The determination of fair value for assets and liabilities in many instances
requires a high degree of estimation. The valuation of intangibles assets, in
particular, is very subjective. We generally use internal cash flow
models and, in certain instances, third party valuations in estimating fair
values. The use of different valuation techniques and assumptions can change the
amounts and useful lives assigned to the assets and liabilities acquired,
including goodwill and other intangible assets and related amortization
expense.
Intangible
Assets
Intangible
assets with estimable useful lives are amortized over respective estimated
useful lives, and reviewed for impairment in accordance with FASB Statement No.
142,
Goodwill and Other
Intangible Assets
.
Recent
Accounting Pronouncements
In
September 2006, the FASB issued FASB Statement 157 “Fair Value Measurements”
(“SFAS No. 157”) that defines and measures fair value and expands
disclosures about fair value measurements. The statement emphasizes that fair
value is a market-based measurement and not an entity-specific measurement. The
provisions of SFAS No. 157 are effective for fiscal years beginning after
November 15, 2007.
In
February 2007, the FASB issued SFAS No. 159,
The Fair Value Option for Financial
Assets and Financial Liabilities
, which permits entities to choose to
measure many financial instruments and certain other items at fair value.
The objective is to improve financial reporting by providing entities with the
opportunity to mitigate volatility in reported earnings caused by measuring
related assets and liabilities differently without having to apply complex hedge
accounting provisions. SFAS No. 159 applies to all entities and is
effective for fiscal years beginning after November 15, 2007.
We do not
expect the adoption of any other recently issued accounting pronouncements to
have a significant impact on their consolidated financial position, results of
operations or cash flow.
ITEM 3.
DESCRIPTION OF
PROPERTY
Labwire’s
headquarters are located at 1514 FM 359, Brookshire, Texas 77423 where it
occupied approximately 2,728 square feet on November 1, 2008 to provide for
daily management operations. Labwire’s base monthly rent is $4,364
through October 31, 2011, $4,801 from November 1, 2011 through October 31, 2014
and $5,237 from November 1, 2014 through October 31, 2018. No
renovations, improvements, or developments are required or anticipated on the
above property. We believe these existing facilities are in good
condition and are adequate for our current needs.
Labwire’s
wholly-owned subsidiary, Occupational Testing, Inc. located in Gillette, Wyoming
leases approximately 1,487 square feet of office space. The office
space is leased through December 31, 2011at the rate of $1,500 per
month. We believe these facilities are in good condition and are
adequate for our current needs.
Labwire
believes that its most important non-current assets are its intellectual
property rights in the Labwire™ Platform discussed above. The only
material tangible property that Labwire owns includes it laboratory equipment,
and office furniture and equipment.
Labwire
carries both General Liability and Renter’s Loss Coverage on these two office
spaces, which management believes is adequate and prudent at the present
time.
ITEM 4.
SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
|
a.
|
Security
ownership of certain beneficial owners. The following table contains each
non-management persons known by us to beneficially own more than 5% of our
outstanding shares as of November 28,
2008.
|
Title
of class
|
Name
and address of
beneficial
owner (1)
|
Amount
and nature of
beneficial
ownership (2)
|
Percentage
Owned(3)
|
Common
Stock
|
Thomas Maring
|
12,000,000
|
8.41%
|
|
Janet Kowalski
|
12,000,000
|
8.41%
|
(1)
|
Unless
otherwise indicated the address of each beneficial owner is care of
Labwire, Inc., 1514 FM 359, Brookshire,
Texas 77423.
|
(2)
|
Beneficial
ownership is determined in accordance with the rules of the Securities and
Exchange Commission. Unless otherwise indicated, this column
reflects amounts as to which the beneficial owner has sole voting power
and sole investment power.
|
(3)
|
Percentage
of ownership is based on 142,699,001 shares of our Common Stock
outstanding on November 28,
2008.
|
|
b.
|
Security
ownership of management. The following table contains certain
information with respect to the beneficial ownership of the common stock
as of November 28, 2008 by the following: (1) each named executive
officer, (2) our director and (3) all of our executive officers and
directors as a group.
|
Title
of class
|
Name
and address of
beneficial
owner (1)
|
Amount
and nature of
beneficial
ownership (2)
|
Percentage
Owned(3)
|
Common
Stock
|
G.
Dexter Morris
|
72,608,000
|
50.88%
|
|
Gary Butler
|
15,000
|
.01%
|
|
Charles Munson
|
15,000
|
.01%
|
|
John S.
Maring
|
24,792,000
|
17.37%
|
All
Officers and Director as a Group(4 Persons)
|
97,430,000
|
68.28%
|
(1)
|
Unless
otherwise indicated the address of each of the executive officers and
directors is care of Labwire, Inc., 1514 FM 359 , Brookshire,
Texas 77423.
|
(2)
|
Beneficial
ownership is determined in accordance with the rules of the Securities and
Exchange Commission. Unless otherwise indicated, this column
reflects amounts as to which the beneficial owner has sole voting power
and sole investment power.
|
(3)
|
Percentage
of ownership is based on 142,699,001 shares of our Common Stock
outstanding on November 28,
2008.
|
|
c.
|
Changes
in control. There are no arrangements which may result in a change in
control of the small business
issuer.
|
ITEM 5.
DIRECTORS AND EXECUTIVE OFFICERS,
PROMOTERS AND CONTROL PERSONS
The
following table sets forth our current directors, officers, and significant
employees, their ages, and all offices and positions with our
Company:
NAME
|
AGE
|
POSITION
|
|
Dexter Morris
|
63
|
Chief
Executive Officer, President & Chairman
|
Charles Munson
|
38
|
Vice
President – Client Services
|
Gary Butler
|
48
|
Vice
President – Sales
|
John S. Maring
|
70
|
Director
|
Biographical
Information of Officers and Directors and Key Employees
The
following is a biographical summary of our executive officers and
directors:
G. Dexter Morris, CEO,
President and Chairman.
Mr. Morris has been our Chief Executive
Officer, President and Chairman of the Board since the inception of the Company
on October 8, 2004. Before founding Labwire, Mr. Morris served
as CEO, President and Chairman of Drug Intervention Services of America (“DISA”)
from 1987 to 2004, which was one of the industry’s premier Third Party
Administrators, which Mr. Morris grew to seven (7) offices and over one
hundred (100) employees nationwide. Mr. Morris has been involved
in the drug testing industry since its inception. He was one of the
five (5) founding Members of the Substance Abuse Program Administrators
Association (“SAPAA”) in 1989, the drug testing industry’s trade and lobbying
arm. Mr. Morris has developed a reputation as an expert on drug
testing issues, including “the Drug Free Workplace Act of 1988”, the Department
of Transportation (“D.O.T.”) drug testing regime [49 CFR, Part 40], and state
regulation of drug testing. He has written various training and
educational texts on drug testing and compliance and has served as spokesman for
the industry both nationally and internationally. Mr. Morris is
a pioneer in the development of non-DOT corporate drug testing policies and
programs and the aggregation of workers data for large, disparate groups
[consortia; oil & gas, contracting, etc.] utilizing data collection and
analysis to enhance the cost-effectiveness of drug testing
programs. He has recently served as the United States’ representative
to the First International Symposium on Workplace Drug Testing in 2005
in Sao Paulo and Rio De Janeiro, Brazil, which began to set international
standards and credentials for drug testing worldwide. Mr. Morris
now voluntarily serves as the Chairman of the nonprofit International
Organization for Drugfree Workplaces (“IODW”) and has spoken at many
international conferences as many nations attempt to standardize drug testing
rules allowing both multinational and local companies to reduce drug use in
their workplaces. Mr. Morris graduated from
Texas Tech University with a bachelor’s degree in Business
Administration where he has participated in a visiting professor program for
several years.
Charles E. Munson, Vice
President – Client Services.
Mr. Munson has been our
Vice President – Client Services since the inception of the Company on October
8, 2004. Before joining Labwire in 2004, Mr. Munson served in
various management positions with Drug Intervention Services of America (“DISA”)
from 1996 to 2004, which was one of the industry’s premier Third Party
Administrators. During his tenure at DISA, Mr. Munson
streamlined the work processes of more than four (4) different departments,
supervised the daily operations of over twenty (20) employees, as well as
managed the program administration for over 30 clients, including some of the
nation’s largest oil and gas corporations. Mr. Munson’s
experience combined with the Labwire platform allows Labwire to operate with the
lowest operational cost per test in the industry. Mr. Munson is
a graduate of Texas A&M University with a bachelor’s degree in
Psychology.
Gary Butler, Vice President –
Sales.
Mr. Butler has been our Vice President –
Sales since the inception of the Company on October 8, 2004. Before
joining Labwire in 2004, Mr. Butler served in various executive sales
positions with Drug Intervention Services of America (“DISA”) from 1995 to 2004,
which was one of the industry’s premier Third Party
Administrators. During his tenure at DISA, Mr. Butler personally
sold in excess of $1 million annually and managed a complete sales and sales
support organization numbering up to 16 individuals
nationally. Heavily experienced in the oil/gas and transportation
industries, he has worked with clients such as Rental Services, Valero, Shell
Oil, and Quality Carriers. With his talent for mathematics and
structure, Mr. Butler lobbied for and spearheaded Labwire’s successful
campaign to become the first and only industry provider to earn the coveted
ISO9001:2000 certification for process management in data storage and retrieval
processes. Mr. Butler graduated in 1981 from
Louisiana College with a bachelor’s degree in Mathematics and in 1987 from
Texas A&M Commerce with a master’s degree in Industrial
Technology.
John S. Maring,
Director.
Mr. Maring has served as a director of Labwire since
the date of our inception on October 8, 2004. Mr. Maring is the Chairman of
Cowlitz Bank and Director of Cowlitz Bancorporation, a community bank located in
Longview, Washington with branches in Portland, Oregon and Bellevue,
Washington. Also, Mr. Maring serves as Chairman of the bank’s
audit committee and on the compensation and governance
committees. Mr. Maring is Chairman of Marshall Christensen
Foundation for higher education worldwide. Mr. Maring is also
General Partner of Endeavour, LP, a real estate and development company with
substantial holdings in the Portland, Oregon area. As a director of
Labwire, Mr. Maring has been involved with the establishment of e-commerce
systems and processes for the delivery of drug-testing products. He
is past Chairman of Marquam Farms Corporation and High Technology Solutions,
which was a defense contractor located in San Diego,
California. Mr. Maring also works closely with
financial community, arranging potential financing
opportunities. Possessing a depth of management skills and a breadth
of experience with start-ups and entrepreneurial organizations, Mr. Maring
is a critical member of Anakam, LLC’s Board of
Directors. Mr. Maring
holds degrees in Chemistry and Business from
Oregon State University. He is a Director and a Founder of
the Kazak-American University in Ust-Kamanogorsk, Kazakastan. In
1996, Mr. Maring was awarded an Honorary Doctorate in Business Humanities
from The Kazak-American University.
Board
of Directors
We
currently have 2 members of the board of directors. Our directors are appointed
for a one-year term to hold office until the next annual meeting of our
stockholders or until removed from office in accordance with our bylaws. The
Board of Directors of Labwire has determined that no member of Labwire’s Board
of Directors is “independent” as that term is defined under the NASDAQ
Marketplace Rules. Our bylaws permit up to 15 members of the board.
Committees
of the Board of Directors
Pursuant
to our amended and restated by-laws, our board of directors may establish
committees of one or more directors from time-to-time, as it deems appropriate.
Currently, the Board of Directors acts as the Audit Committee, and the Board has
no separate committees.
Involvement
in Certain Legal Proceedings
No
director, person nominated to become a director, executive officer, promoter or
control persons of our company has been involved during the last five years in
any of the following events that are material to an evaluation of his ability or
integrity:
|
· Bankruptcy petitions filed by or against any business of which such
person was a general partner or executive officer either at the time of
the bankruptcy or within two years prior to that
time.
|
|
· Conviction in a criminal proceeding or being subject to a pending
criminal proceeding (excluding traffic violations and other minor
offenses).
|
|
· Being subject to any order, judgment or decree, not subsequently
reversed, suspended or vacated, of any court of competent jurisdiction,
permanently or temporarily enjoining, barring or suspending or otherwise
limiting his involvement in any type of business, securities or banking
activities, or
|
|
· Being found by a court of competition jurisdiction (in a civil action),
the Securities and Exchange Commission or the Commodities Futures Trading
Commission to have violated a federal or state securities or commodities
law, and the judgment has not been reversed, suspended or
vacated.
|
ITEM 6.
EXECUTIVE
COMPENSATION.
The
following table sets forth the compensation awarded to, earned by or paid to our
executive officers as a group or directors for all services rendered in all
capacities for the nine months ended September 30, 2008 and the fiscal years
ended December 31, 2007 and 2006.
Summary
Compensation Table
Name
and Principal Position
|
Year
|
Salary
($)
|
|
Bonus
($)
|
|
Other
Annual
Compensation
($)
|
|
Securities
Underlying
Options
(#)
|
|
Long-Term
Compensation
Awards
|
|
All
Other
Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
G.
Dexter Morris,
|
2006
|
$120,000
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
CEO
& Chairman
|
2007
|
$158,500
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
2008*
|
$134,810
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gary Butler,
|
2006
|
$70,000
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
Vice
President – Sales
|
2007
|
$76,923
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
2008*
|
$84,654
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charles
Munson,
|
2006
|
$68,000
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
V P
–Client Relations
|
2007
|
$73,950
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
2008*
|
$56,342
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Represents
compensation for nine months ended September 30, 2008.
We may
hire additional executive officers and/or change the compensation paid to and
benefits received by our current executive officers, as our Board of Directors
deems advisable or necessary. To date, the Company’s Board of Directors has not
adopted any retirement, pension, profit sharing or other similar programs for
our executive officers.
Employment
Agreements with Executive Officers
The
Company does not have any employment agreements with its officers and employees.
All employees serve at the pleasure of the Board of Directors and the
Company.
Equity
Incentive Plan
The
Company has no equity incentive plan at this time.
Director
Compensation
The
Company’s Directors are not currently compensated for serving as a member of the
Board of Directors.
ITEM 7.
CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS AND DIRECTOR INDEPENDENCE
Labwire
(dba Labwire Security, Inc.) contracts with American K-9 Bomb Search, Inc.,
which is one-half owned by Labwire’s Chairman and Chief Executive Officer, to
perform security services. Labwire Security, Inc. is fully licensed
with the State of Texas. This security model features a web based
solution for reporting and record keeping delivered with a traditional hand on
type product giving client security managers the ability to manage more
locations more securely, effectively, and at lower costs. A typical
weekly consolidated, online report to a client would contain the numbers and
types of vehicles entering, license plates numbers, rail and marine traffic,
incident reports, the times of entering and leaving, observations of persons and
contents, etc. These reports now allow for the efficient use of
resources by security services and client resources to be managed globally
rather than autonomously as now done in most industries.
Labwire
is paid a 5% commission for the K-9 security services that it refers to Labwire
Security, Inc. The commissions received by the Company have been less
than 1% of the Company’s gross revenues.
Affiliate
Investments
As of
December 31, 2007, G. Dexter Morris, Chairman of our Board of
Directors and President, had a loan of $53,236 to the Company that is due on
demand and bears interest at the rate of 1.71% per annum. This note was
retired during the quarter ended June 30, 2008.
As of
December 31, 2007, John S. Maring, Director, had a loan of $60,756 to
the Company that is due on demand and bears interest at the rate of 1.71% per
annum. This note was retired during the quarter ended June 30,
2008.
Recent
Compensatory Grants
None
Director
Independence
Presently,
we are not required to comply with the director independence requirements of any
securities exchange. In determining whether our directors are independent,
however, we intend to comply with the rules of the American Stock Exchange LLC,
or the AMEX. The board of directors also will consult with counsel to
ensure that the board of directors’ determinations are consistent with those
rules and all relevant securities and other laws and regulations regarding the
independence of directors, including those adopted under the Sarbanes-Oxley Act
of 2002 with respect to the independence of audit committee members. The
AMEX listing standards define an “independent director” generally as a person,
other than an officer of a company, who does not have a relationship with the
company that would interfere with the director’s exercise of independent
judgment.
Currently
we do not satisfy the “independent director” requirements of the American Stock
Exchange, which requires that a majority of a company’s directors be
independent. Our board of directors intends to appoint additional members,
each of whom will satisfy such independence requirements.
ITEM
8. LEGAL PROCEEDINGS.
None
ITEM
9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT’S
COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Our
Common Stock is quoted over-the-counter on the Pink Sheets, LLC
(www.pinksheets.com) electronic quotation service for OTC securities under the
trading symbol “LBWR,” but is not quoted on the NASD OTC Bulletin Board or
NASDAQ, nor listed on any national or regional securities exchange.
The
following table sets forth the range of the high and low bid prices by quarter
as reported on the over-the-counter market since March 31,
2006. Quotations from Pink Sheets LLC reflect inter-dealer prices
without adjustments for retail markups, markdowns or conversions and may not
represent actual transactions.
Quarter-End
Date
|
Low
Bid
|
High
Bid
|
March
31, 2006
|
$.05
|
$.20
|
June
30, 2006
|
$.06
|
$.21
|
September
30, 2006
|
$.09
|
$.17
|
December
31, 2006
|
$.09
|
$.16
|
|
|
|
March
31, 2007
|
$.07
|
$.11
|
June
30, 2007
|
$.05
|
$.11
|
September
30, 2007
|
$.07
|
$.20
|
December
31, 2007
|
$.03
|
$.18
|
|
|
|
March
31, 2008
|
$.12
|
$.16
|
June
30, 2008
|
$.08
|
$.14
|
September
30, 2008
|
$.05
|
$.08
|
The
Securities and Exchange Commission has adopted regulations, which generally
define “penny stock” to be any equity security that has a market price less than
$5.00 per share or an exercise price of less than $5.00 per share, subject to
certain exceptions. Our common stock is currently a “penny stock” as defined in
the Exchange Act. As a result, an investor may find it more difficult to dispose
of or obtain accurate quotations as to the price of the shares of the common
stock. In addition, the “penny stock” rules adopted by the SEC under
the Exchange Act subject the sale of the shares of the common stock to certain
regulations which impose sales practice requirements on broker-dealers. For
example, broker-dealers selling such securities must provide, prior to effecting
the transaction, their customers with a document that discloses the risks of
investing in such securities. Included in this document are the
following:
—
|
The
bid and offer price quotes for the penny stock, and the number of shares
to which the quoted prices apply,
|
—
|
The
brokerage firm’s compensation for the trade, and
|
—
|
The
compensation received by the brokerages firm’s salesperson for the
trade.
|
In
addition, the brokerage firm must send to the investor monthly account statement
that gives an estimate of the value of each penny stock in the investor’s
account, and a written statement of the investor’s financial situation and
investment goals. These disclosure and other requirements may have the effect of
reducing the level of trading activity in the secondary market for the stock
that is subject to these penny stock rules. Consequently, these penny stock
rules may affect the ability of broker-dealers to trade our securities. The
penny stock rules may discourage investor interest in and limit the
marketability of our Common Stock.
Holders
of our Common Stock
According
to our transfer agent, Holliday Stock Transfer, Inc., as of September 30, 2008,
there were 82 record holders of shares of our Common Stock and additional
stockholders held shares in street name.
Dividends
Labwire
has not paid any cash dividends to date and does not anticipate or contemplate
paying dividends in the near future. It is our present intention to utilize all
available funds for the development of our business.
Securities
Authorized for Issuance under Equity Compensation Plans
We do not
have any compensation plans under which equity securities were authorized to be
issued as of the end of our last fiscal year.
ITEM
10. RECENT SALES OF UNREGISTERED SECURITIES
The
Company has sold certain shares of stock for cash and has issued shares in
exchange for services. The sale and issuance of the shares of stock were exempt
from registration under the Securities Act of 1933, as amended, by virtue of
section 4(2) and, in other cases, in accordance with Rule 701. Purchasers in
transactions exempt under Section 4(2) purchased shares from the Company for
investment and not with a view to distribution to the public.
On
December 3, 2004, the Company purchased its wholly owned subsidiary Workplace
Screening Services, Inc. from related parties, Dexter Morris – Chairman and CEO,
John Maring – Director and Vice President, Thomas Maring and Janet Kowalski for
120,000,000 shares of restricted common stock valued at $120,000 and the
assumption of $467,352 of liabilities.
In
December of 2004, the Company sold 125,000 shares of this restricted common
stock for $5,750, which the Company issued in private placements to accredited
investors.
In the
year ended December 31, 2005, the Company sold 16,107,330 shares in private
placements to accredited investors for $178,828 in cash.
In the
year ended December 31, 2006, the Company sold 4,177,670 shares in private
placements to accredited investors for $307,205 in cash.
During
the second quarter of 2008, the Company issued an aggregate of 2,200,000 shares
of its common stock to its two directors in exchange for the cancellation of
promissory notes that we executed in favor of them in the aggregate principal
amount of approximately $181,151.
During
the first quarter of 2008, the Company sold 100,000 shares of its common stock
to a single accredited investor at a per share price of $0.15.
Each
certificate issued for unregistered securities contained a legend stating that
the securities have not been registered under the Act and setting forth the
restrictions on the transferability and the sale of the securities. No
underwriter participated in, nor did the Company pay any commissions or fees to
any underwriter in connection with any of these transactions. None of the
transactions involved a public offering. All of the persons below are
sophisticated investors, are familiar with our business activities and were
given full and complete access to any corporate information requested by
them.
ITEM
11. DESCRIPTION OF SECURITIES
Common
Stock
We are
currently authorized to issue 200,000,000 shares of common stock, par value
$.001 per share. The following is a summary description of our
capital stock and certain provisions of our certificate of incorporation and
by-laws, copies of which have been incorporated by reference as exhibits to the
registration statement of which this prospectus forms a part. The following
discussion is qualified in its entirety by reference to such
exhibits. As of September 30, 2008, there were 142,699,001 shares of
common stock outstanding. Holders of common stock are entitled to
receive ratably such dividends, if any, as may be declared by the Board of
Directors out of fund legally available therefore. Upon the
liquidation, dissolution, or winding up of our company, the holders of common
stock are entitled to share ratably in all of our assets, which are legally
available for distribution after payment of all debts and other liabilities and
liquidation preference of any outstanding preferred stock. The
outstanding shares of common stock are validly issued, fully paid and
non-assessable.
On May
22, 2008, the Board of Directors and Shareholders owning a majority of the
issued and outstanding common stock voted to amend its articles of incorporation
to increase the authorized common shares to 200,000,000, par value
$0.001. The amended articles of incorporation have been filed with
the Nevada Secretary of State.
Holders
of our Common Stock are entitled to one vote per share on all matters to be
voted upon by stockholders. All shares of Common Stock rank equally as to voting
and all other matters. The shares of Common Stock have no preemptive or
conversion rights, no redemption or sinking fund provisions and are not entitled
to cumulative voting rights. Holders of our Common Stock are entitled to receive
dividends when and as declared by the board of directors out of funds legally
available for dividends.
The
Common Stock of Labwire is currently quoted on the over-the-counter Pink Sheets
LLC electronic quotation service under the symbol “LBWR.PK.”
The
Company has not effectuated a change of control, or an increase in its
authorized common stock. There are no past, pending or anticipated
stock splits, stock dividends, recapitalizations, mergers, acquisitions,
spin-off, or reorganizations.
Transfer
Agent
The
transfer agent and registrar for our Common Stock is Holliday Stock Transfer,
Inc., 2939 N. 67th Place, Scottsdale, AZ, 85251.
Anti-Takeover
Effects of Provisions of Nevada State Law
We may be
or in the future, we may become subject to Nevada’s control share law. A
corporation is subject to Nevada’s control share law if it has more than 200
stockholders, at least 100 of whom are stockholders of record and residents of
Nevada, and it does business in Nevada or through an affiliated
corporation.
The law
focuses on the acquisition of a “controlling interest” which means the ownership
of outstanding voting shares sufficient, but for the control share law, to
enable the acquiring person to exercise the following proportions of the voting
power of the corporation in the election of directors: (i) one-fifth or more but
less than one-third, (ii) one-third or more but less than a majority, or (iii) a
majority or more. The ability to exercise such voting power may be direct or
indirect, as well as individual or in association with others.
The
effect of the control share law is that the acquiring person, and those acting
in association with it, obtains only such voting rights in the control shares as
are conferred by a resolution of the stockholders of the corporation, approved
at a special or annual meeting of stockholders. The control share law
contemplates that voting rights will be considered only once by the other
stockholders. Thus, there is no authority to strip voting rights from the
control shares of an acquiring person once those rights have been approved. If
the stockholders do not grant voting rights to the control shares acquired by an
acquiring person, those shares do not become permanent non-voting shares. The
acquiring person is free to sell its shares to others. If the buyers of those
shares themselves do not acquire a controlling interest, the control share law
does not govern their shares.
If
control shares are accorded full voting rights and the acquiring person has
acquired control shares with a majority or more of the voting power, any
stockholder of record, other than an acquiring person, who has not voted in
favor of approval of voting rights, is entitled to demand fair value for such
stockholder’s shares. Nevada’s control share law may have the effect
of discouraging takeovers of the corporation. In addition to the control share
law, Nevada has a business combination law, which prohibits certain business
combinations between Nevada corporations, and “interested stockholders” for
three years after the “interested stockholder” first becomes an “interested
stockholder” unless the corporation’s board of directors approves the
combination in advance. For purposes of Nevada law, an “interested stockholder”
is any person who is (i) the beneficial owner, directly or indirectly, of ten
percent or more of the voting power of the outstanding voting shares of the
corporation, or (ii) an affiliate or associate of the corporation and at any
time within the three previous years was the beneficial owner, directly or
indirectly, of ten percent or more of the voting power of the then outstanding
shares of the corporation. The definition of the term “business combination” is
sufficiently broad to cover virtually any kind of transaction that would allow a
potential acquirer to use the corporation’s assets to finance the acquisition or
otherwise to benefit its own interests rather than the interests of the
corporation and its other stockholders.
The
effect of Nevada’s business combination law is to discourage parties interested
in taking control of the Company from doing so if it cannot obtain the approval
of our board of directors.
ITEM 12. INDEMNIFICATION OF
DIRECTORS AND OFFICERS
Our
officers and directors are indemnified as provided by the Nevada Revised
Statutes and the Company’s bylaws. Under the Nevada Revised Statutes, director
immunity from liability to a company or its shareholders for monetary
liabilities applies automatically unless it is specifically limited by a
company’s Articles of Incorporation. Our Articles of Incorporation do not
specifically limit the directors’ immunity. Excepted from that immunity
are: (a) a willful failure to deal fairly with the company or its shareholders
in connection with a matter in which the director has a material conflict of
interest; (b) a violation of criminal law, unless the director had reasonable
cause to believe that his or her conduct was lawful or no reasonable cause to
believe that his or her conduct was unlawful; (c) a transaction from which the
director derived an improper personal profit; and (d) willful
misconduct.
Our
bylaws provide that we will indemnify the directors to the fullest extent not
prohibited by Nevada law; provided, however, that we may modify the extent of
such indemnification by individual contracts with the directors and officers;
and, provided, further, that we shall not be required to indemnify any director
or officer in connection with any proceeding, or part thereof, initiated by such
person unless such indemnification: (a) is expressly required to be made by law,
(b) the proceeding was authorized by the board of directors, (c) is provided by
us, in our sole discretion, pursuant to the powers vested us under Nevada law or
(d) is required to be made pursuant to the bylaws.
Our
bylaws provide that we will advance to any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action,
suit or proceeding, whether civil, criminal, administrative or investigative, by
reason of the fact that he is or was a director or officer, of us, or is or was
serving at the request of us as a director or executive officer of another
company, partnership, joint venture, trust or other enterprise, prior to the
final disposition of the proceeding, promptly following request therefore, all
expenses incurred by any director or officer in connection with such proceeding
upon receipt of an undertaking by or on behalf of such person to repay said
amounts if it should be determined ultimately that such person is not entitled
to be indemnified under the bylaws or otherwise.
Our
bylaws provide that no advance shall be made by it to an officer of us except by
reason of the fact that such officer is or was a director of the Company in
which event this paragraph shall not apply, in any action, suit or proceeding,
whether civil, criminal, administrative or investigative, if a determination is
reasonably and promptly made: (a) by the board of directors by a majority vote
of a quorum consisting of directors who were not parties to the proceeding, or
(b) if such quorum is not obtainable, or, even if obtainable, a quorum of
disinterested directors so directs, by independent legal counsel in a written
opinion, that the facts known to the decision-making party at the time such
determination is made demonstrate clearly and convincingly that such person
acted in bad faith or in a manner that such person did not believe to be in or
not opposed to the best interests of the Company.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may
be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been
advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
INSOFAR
AS INDEMNIFICATION FOR LIABILITIES ARISING UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, MAY BE PERMITTED TO DIRECTORS, OFFICERS OR PERSONS CONTROLLING THE
COMPANY PURSUANT TO THE FOREGOING PROVISIONS, IT IS THE OPINION OF THE
SECURITIES AND EXCHANGE COMMISSION THAT SUCH INDEMNIFICATION IS AGAINST PUBLIC
POLICY AS EXPRESSED IN THE ACT AND IS THEREFORE UNENFORCEABLE.
Item
13. Financial Statements and Supplementary Data
See pages
F-1 to F-29 attached hereto for financial statements and supplementary
data.
Item 14. Changes In And
Disagreements With Accountants On Accounting And Financial
Disclosure
During
the fiscal year ended December 31, 2007, 2006 and 2005, we engaged Moore &
Associates, Chartered Accountants and Advisors as our principal accountant for
the purposes of auditing our financial statements. There are not and
have not been any disagreements between the Company and our accountants on any
matter of accounting principles, practices or financial statement
disclosure.
Item
15. Financial Statement and Exhibits
a)
Financial Statements
|
Consolidated
Financial Statements:
|
F-2
|
Report
of Independent Registered Public Accounting Firm
|
F-3
|
Condensed
Consolidated Balance Sheet at September 30, 2008 (Unaudited) and December
31, 2008 (Restated)
|
F-4
|
Condensed
Consolidated Statements of Operations for the three and nine months ended
September 30, 2008 and 2007 (Unaudited)
|
F-5
|
Condensed
Consolidated Statement of Stockholders’ Deficit for the nine months ended
September 30, 2008 (Unaudited)
|
F-6
|
Condensed
Consolidated Statements of Cash Flows for the nine months ended September
30, 2008 and 2007 (Unaudited)
|
F-7
|
Notes
to Condensed Consolidated Financial Statements (Unaudited)
|
|
Condensed
Consolidated Financial Statements (unaudited):
|
F-16
|
Report
of Independent Registered Public Accounting Firm
|
F-17
|
Consolidated
Balance Sheet as of December 31, 2007 (Restated) and
2006
|
F-18
|
Consolidated
Statements of Operations for the years ended December 31, 2007 (Restated)
and 2006
|
F-19
|
Consolidated
Statement of Stockholders’ Deficit for the years ended December 31, 2007
(Restated) and 2006
|
F-20
|
Consolidated
Statements of Cash Flows for the years ended December 31, 2007 (Restated)
and 2006
|
F-21
|
Notes
to Consolidated Financial Statements for the years ended December 31, 2007
(Restated) and 2006
|
b)
Exhibits
The
following exhibits are included as part of this Form 10. References to “the
Company” in this Exhibit List mean Labwire, Inc., a Nevada corporation.
The
Exhibits attached herewith have been formatted in accordance with the SEC.
The original executed documents, signed, stamped and sealed, are on
record at the offices of Labwire, Inc.
Exhibit
Number
|
Description
|
3.1*
|
Articles
of Incorporation of Labwire, Inc., dated October 8,
2004
|
3.1.1
|
Amended
Articles of Incorporation of Labwire, Inc. dated September 19,
2008.
|
3.2*
|
Nevada
Secretary of State Certificate
|
3.3*
|
By-laws
of Labwire, Inc.
|
10.1
|
Agreement
and Promissory Note for Purchase of Occupational Testing,
Inc.
|
10.2
|
Alliance
Agreement with USIS Commercial Services, Inc.
|
10.3
|
Master
Service Agreement with Laboratory Corporation of America
Holdings
|
10.5
|
Agreement
with Connex North America, Inc. (now Veolia) for
services
|
10.6
|
Agreement
with ARAMARK Management Services for services
|
10.7
|
Agreement
with Greyhound Lines, Inc. for Services
|
10.8
|
Agreement
with Boeing for Services
|
10.9
|
Lease
Agreement with FM358 LTD for office space in Brookshire,
Texas
|
10.10
|
Lease
Agreement with Michael and Christina Geis for office space in
Wyoming
|
10.13
|
Agreement
with Marlin Williford for Services
|
10.14
|
Agreement
with American K-9 Bomb Search, Inc.
|
10.15
|
Purchase
Order From Lockheed for Services
|
10.16
|
Agreement
with Shell Chemical for Services
|
10.17
|
US
Patent and Trademark Office Notice on
Trademark Registration
|
10.18
|
Loan
Agreement with Frost Bank for $300,000 due February 13,
2010
|
10.19
|
Loan
Agreement with Frost Bank for $241,932 due March 4,
2011
|
10.20
|
Security
Agreement for Frost Bank $300,000 Loan
|
10.21
|
Security
Agreement for Frost Bank $241,932 Loan
|
14.1*
|
Code
of Ethics
|
15.1
|
Consent
of Independent Registered Public Accounting Firm for Interim
Financials
|
21.1
|
Subsidiaries
of Registrant
|
23.1
|
Consent
of Independent Registered Public Accounting Firm for Annual
Financials
|
*Previously
filed and attached herewith.
SIGNATURES
In
accordance with Section 12 of the Securities Exchange Act of 1934, the
registrant caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
LABWIRE,
INC.
|
Date:
December 23, 2008
|
By:
/s/
G. Dexter Morris
|
|
Name:
G. Dexter Morris
|
|
Title: Chief
Executive Officer,
Principal
Financial Officer and
Director
|
Financial
Statements
Labwire,
Inc.
Table
of Contents
INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS
|
Consolidated
Financial Statements:
|
F-2
|
Report
of Independent Registered Public Accounting Firm
|
F-3
|
Condensed
Consolidated Balance Sheet at September 30, 2008 (Unaudited) and December
31, 2008 (Restated)
|
F-4
|
Condensed
Consolidated Statements of Operations for the three and nine months ended
September 30, 2008 and 2007 (Unaudited)
|
F-5
|
Condensed
Consolidated Statement of Stockholders’ Deficit for the nine months ended
September 30, 2008 (Unaudited)
|
F-6
|
Condensed
Consolidated Statements of Cash Flows for the nine months ended September
30, 2008 and 2007 (Unaudited)
|
F-7
|
Notes
to Condensed Consolidated Financial Statements (Unaudited)
|
|
Condensed
Consolidated Financial Statements (unaudited):
|
F-16
|
Report
of Independent Registered Public Accounting Firm
|
F-17
|
Consolidated
Balance Sheet as of December 31, 2007 (Restated) and
2006
|
F-18
|
Consolidated
Statements of Operations for the years ended December 31, 2007 (Restated)
and 2006
|
F-19
|
Consolidated
Statement of Stockholders’ Deficit for the years ended December 31, 2007
(Restated) and 2006
|
F-20
|
Consolidated
Statements of Cash Flows for the years ended December 31, 2007 (Restated)
and 2006
|
F-21
|
Notes
to Consolidated Financial Statements for the years ended December 31, 2007
(Restated) and 2006
|
MOORE
& ASSOCIATES, CHARTERED
ACCOUNTANTS AND
ADVISORS
PCAOB
REGISTERED
REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
To the
Board of Directors
Labwire,
Inc.
We have
reviewed the accompanying condensed consolidated balance sheet of Labwire, Inc.
as of September 30, 2008, and the related condensed consolidated statements of
operations, stockholders’ equity (deficit), and cash flows for the three-month
and nine-month periods ended September 30, 2008 and 2007. These interim
financial statements are the responsibility of the Corporation’s
management.
We
conduct our reviews in accordance with the standards of the Public Company
Accounting Oversight Board (United States). A review of interim financial
information consists of principally applying analytical procedures and making
inquiries of persons responsible for the financials and accounting matters. It
is substantially less in scope than an audit conducted in accordance with the
standards of the Public Company Accounting Oversight Board (United States), the
objective of which is the expression of an opinion regarding the financial
statements taken as a whole. Accordingly, we do not express such an
opinion.
Based on
our reviews, we are not aware of any material modifications that should be made
to such condensed consolidated financial statements for them to be in conformity
with accounting principles generally accepted in the United States of
America.
We have
previously audited, in accordance with standards of the Public Company
Accounting Oversight Board (United States), the restated balance sheets of
Labwire, Inc. as of December 31, 2007 and 2006, and the related restated
consolidated statements of income, stockholders’ equity and cash flows for the
years then ended (not presented herein); and in our report dated December 12,
2008, we expressed an opinion on those financial statements. In our
opinion, the information set forth in the accompanying restated balance sheets
as of December 31, 2007 and 2006 is fairly stated, in all material respects, in
relations to the restated balance sheets from which it has been
derived.
/s/
Moore & Associates, Chartered
Moore
& Associates, Chartered
Las
Vegas, Nevada
December
12, 2008
6490 WEST DESERT INN RD, LAS VEGAS, NEVADA 89146 (702)
253-7499 Fax: (702)253-7501
F-2
LABWIRE,
INC.
Condensed
Consolidated Balance Sheets
|
|
9/30/2008
|
12/31/2007
|
|
|
(Unaudited)
|
(Restated)
|
ASSETS
|
|
|
|
CURRENT
ASSETS:
|
|
|
|
Cash
and cash equivalents - interest bearing
|
|
$ 77,485
|
$ 206,520
|
Accounts
receivable, net of allowance for doubtful accounts of $5,600 as
of
September
30, 2008 and December 31, 2007, respectively
|
|
991,945
|
860,098
|
Advances
to employees
|
|
26,405
|
-
|
Prepaid
expenses
|
|
29,259
|
20,696
|
Total
Current Assets
|
|
1,125,094
|
1,087,314
|
|
|
|
|
PROPERTY
AND EQUIPMENT:
|
|
|
|
Laboratory
equipment
|
|
53,781
|
53,781
|
Vehicles
|
|
7,000
|
7,000
|
Office
furniture and equipment
|
|
51,115
|
35,251
|
Proprietary
software
|
|
237,703
|
118,550
|
|
|
349,599
|
214,582
|
Less: accumulated
depreciation
|
|
(95,866)
|
(54,207)
|
Total
Property and Equipment
|
|
253,733
|
160,375
|
|
|
|
|
OTHER
ASSETS:
|
|
|
|
Goodwill
|
|
455,210
|
455,210
|
|
|
|
|
TOTAL
ASSETS
|
|
$ 1,834,037
|
$ 1,702,899
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ EQUITY (DEFICIT)
|
|
|
|
CURRENT
LIABILITIES:
|
|
|
|
Accounts
payable and accrued expenses
|
|
387,992
|
866,796
|
Income
taxes payable
|
|
17,939
|
24,303
|
Current
portion of long-term debt
|
|
520,326
|
401,932
|
Notes
payable to related parties
|
|
-
|
156,985
|
Accrued
interest payable
|
|
35,231
|
7,045
|
Accrued
interest payable – related parties
|
|
-
|
21,690
|
Total
Current Liabilities
|
|
961,488
|
1,478,751
|
|
|
|
|
LONG-TERM
LIABILITIES:
|
|
|
|
Long
term-debt, less current portion above
|
|
626,883
|
320,000
|
Total
Long-term Liabilities
|
|
626,883
|
320,000
|
|
|
|
|
TOTAL
LIABILITIES
|
|
1,588,371
|
1,798,751
|
|
|
|
|
STOCKHOLDERS’
EQUITY (DEFICIT):
|
|
|
|
Common
stock; $0.001par value; 200,000,000 shares authorized; 142,699,001 shares
issued
and outstanding at September 30, 2008 and 140,399,001 shares at
December 31, 2007
|
|
142,699
|
140,399
|
Additional
paid-in capital
|
|
665,235
|
471,384
|
Accumulated
deficit
|
|
(562,268)
|
(707,635)
|
|
|
|
|
Total
Stockholders’ Equity (Deficit)
|
|
245,666
|
(95,852)
|
|
|
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
|
|
$ 1,834,037
|
$ 1,702,899
|
The
accompanying notes are an integral part of these financial
statements.
F-3
LABWIRE,
INC.
Condensed
Consolidated Statements of Operations
|
For
the Three Months Ended
September
30
|
|
For
the Nine Months Ended
September
30
|
|
2008
|
2007
|
|
2008
|
2007
|
|
|
|
|
|
|
REVENUES
|
$ 1,292,472
|
$ 1,352,671
|
|
$ 3,168,726
|
$ 3,529,956
|
COST
OF SALES
|
747,665
|
927,084
|
|
1,707,178
|
2,285,302
|
GROSS
PROFIT
|
544,807
|
425,587
|
|
1,461,548
|
1,244,654
|
|
|
|
|
|
|
OPERATING
EXPENSES:
|
|
|
|
|
|
General
and administrative expenses
|
167,173
|
96,952
|
|
529,194
|
402,066
|
Bad
debt expense
|
365
|
-
|
|
2,366
|
490
|
Advertising
and marketing expense
|
6,520
|
1,750
|
|
15,896
|
2,938
|
Payroll
expenses
|
208,879
|
154,278
|
|
674,160
|
443,752
|
|
|
|
|
|
|
Total
Operating Expenses
|
382,937
|
252,980
|
|
1,221,616
|
849,246
|
|
|
|
|
|
|
OPERATING
INCOME
|
161,870
|
172,607
|
|
239,932
|
395,408
|
|
|
|
|
|
|
OTHER
INCOME (EXPENSES)
|
|
|
|
|
|
Interest
expense
|
(40,026)
|
(12,645)
|
|
(93,002)
|
(25,197)
|
Interest
income
|
-
|
-
|
|
78
|
-
|
Total
Other Income (Expenses)
|
(40,026)
|
(12,645)
|
|
(92,925)
|
(25,197)
|
|
|
|
|
|
|
NET
INCOME BEFORE TAXES
|
121,844
|
159,962
|
|
147,007
|
370,211
|
|
|
|
|
|
|
INCOME
TAX EXPENSE (BENEFIT)
|
4,049
|
-
|
|
1,640
|
32,086
|
|
|
|
|
|
|
NET
INCOME
|
$ 117,795
|
$ 159,962
|
|
$ 145,367
|
$ 338,125
|
|
|
|
|
|
|
BASIC
EARNINGS PER SHARE
|
$ 0.00
|
$ 0.00
|
|
$ 0.00
|
$ 0.00
|
|
|
|
|
|
|
WEIGHTED
AVERAGE NUMBER OF SHARES OUTSTANDING
|
140,654,557
|
140,399,001
|
|
140,654,557
|
140,399,001
|
The
accompanying notes are an integral part of these financial
statements.
F-4
LABWIRE,
INC.
Condensed
Consolidated Statement of Stockholders’ Equity (Deficit)
DESCRIPTION
|
Common
Shares
|
Stock
Amount
|
|
Additional
Paid-In
Capital
|
|
Accumulated
Deficit
|
|
Total
Stockholders’
Equity
(Deficit)
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2005
|
136,232,330
|
$136,232
|
|
$168,346
|
|
$(310,401)
|
|
$(5,823)
|
|
|
|
|
|
|
|
|
|
Common
shares issued for cash
|
4,166,671
|
4,167
|
|
303,038
|
|
-
|
|
307,205
|
|
|
|
|
|
|
|
|
|
Net
loss for the year ended December 31, 2006
|
-
|
-
|
|
-
|
|
(500,981)
|
|
(500,981)
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2006
|
140,399,001
|
140,399
|
|
471,384
|
|
(811,382)
|
|
(199,599)
|
|
|
|
|
|
|
|
|
|
Net
income for the year ended December 31, 2007 (Restated)
|
-
|
-
|
|
-
|
|
103,747
|
|
103,747
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2007 (Restated)
|
140,399,001
|
140,399
|
|
471,384
|
|
(707,635)
|
|
(95,852)
|
|
|
|
|
|
|
|
|
|
Common
stock issued for cash
|
100,000
|
100
|
|
14,900
|
|
|
|
15,000
|
|
|
|
|
|
|
|
|
|
Issuance
of common stock to retire debt
|
2,200,000
|
2,200
|
|
178,951
|
|
|
|
181,151
|
Net
income for the nine months ended September 30, 2008
|
-
|
-
|
|
-
|
|
145,367
|
|
145,367
|
|
|
|
|
|
|
|
|
|
Balance,
September 30, 2008
|
142,699,001
|
$142,699
|
|
$665,235
|
|
$(562,268)
|
|
$245,666
|
The
accompanying notes are an integral part of these financial
statements.
F-5
LABWIRE,
INC.
Condensed
Consolidated Statements of Cash Flows
|
For
the Nine Months Ended
September
30
|
|
2008
|
2007
|
OPERATING
ACTIVITIES
|
|
|
Net
income
|
$ 145,367
|
$ 338,125
|
|
|
|
Adjustments
to reconcile net income (loss) to net cash provided (used) by operating
activities:
|
|
|
Depreciation
|
41,659
|
14,071
|
Changes
in operating assets and liabilities
|
|
|
(Increase)
decrease in accounts receivable
|
(158,252)
|
(296,281)
|
(Increase)
decrease in prepaid expenses
|
(8,563)
|
1,382
|
Increase
(decrease) in accounts payable and accrued expenses
|
(478,804)
|
17,109
|
Increase
(decrease) in accrued interest payable
|
6,496
|
(19,547)
|
Income
taxes payable
|
(6,364)
|
18,295
|
Net
Cash Provided by (Used) in Operating Activities
|
(458,461)
|
73,154
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES
|
|
|
Purchase
of property and equipment
|
(15,864)
|
(61,496)
|
Development
of Software
|
(119,153)
|
-
|
Net
Cash Used in Investing Activities
|
(135,017)
|
(61,496)
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES
|
|
|
Repayment
of notes payable
|
(150,557)
|
(66,165)
|
Increase
in bank line of credit
|
300,000
|
121,933
|
Sale
of common stock
|
15,000
|
|
Increase
in notes payable
|
300,000
|
76,588
|
Net
Cash Provided by Financing Activities
|
464,443
|
132,356
|
|
|
|
NET
INCREASE (DECREASE) IN CASH
|
(129,035)
|
144,014
|
|
|
|
CASH
AT BEGINNING OF YEAR
|
206,520
|
108,346
|
|
|
|
CASH
AT END OF PERIOD
|
$ 77,485
|
$ 252,360
|
|
|
|
CASH
PAID FOR:
|
|
|
Interest
|
$ 57,770
|
$ 3,666
|
Income
Taxes
|
$ -
|
$ 6,022
|
The
accompanying notes are an integral part of these financial
statements.
F-6
Labwire,
Inc.
Notes to
Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
1.
Summary of Significant Accounting Policies
Nature of
Operations
-
Labwire, Inc. (referred to herein as “the Company”)
was incorporated in Nevada on October 8, 2004. The Company was established as an
employee screening company specializing in drug testing, background
investigations, employee training, on-line certification and security with a
client base of large US and European corporations. It provides compliance
services for Department of Transportation (49CFR Part 40) and Federal Trade
Commission (Fair Credit Reporting Act) governed
programs.
Basis
of Consolidation
–
The consolidated financial statements include
the accounts of the Company and its two wholly-owned
subsidiaries. All intercompany balances and transactions have been
eliminated in consolidation.
Basis
of Presentation
- The accompanying financial statements have been
prepared on the accrual basis of accounting in accordance with accounting
principles generally accepted in the United States of America (“U.S. GAAP”).
Significant accounting principles followed by the Company and the methods of
applying those principles, which materially affect the determination of
financial position and cash flows, are summarized below.
In the
opinion of management, the accompanying balance sheets and related interim
statements of income, cash flows, and stockholders’ equity include all
adjustments, consisting only of normal recurring items, necessary for their fair
presentation in conformity with GAAP. Preparing financial statements
requires management to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenues, and expenses. Actual
results and outcomes may differ from management’s estimates and
assumptions.
Interim
results are not necessarily indicative of results for a full
year. The information included in this quarterly report should be
read in conjunction with information included in the annual financial
statements.
Cash and
Cash Equivalents
- For purposes of the statement of cash flows, the
Company considers all highly liquid instruments with original maturities of
ninety days or less to be cash equivalents.
Allowance
for Uncollectible Receivables
- The allowance for all probable
uncollectible receivables is based on a combination of historical data, cash
payment trends, specific customer issues, write-off trends, general economic
conditions and other factors. These factors are continuously monitored by
management to arrive at an estimate for the amount of accounts receivable that
may ultimately be uncollectible. In circumstances where the Company is aware of
a specific customer’s inability to meet its financial obligations, the Company
records a specific allowance for bad debts against amounts due, in order to
reduce the net recognized receivable to the amount it reasonably believes will
be collected. This analysis requires making significant estimates, and changes
in facts and circumstances could result in material changes in the allowance for
uncollectible receivables. The Company’s allowance for uncollectible
receivables was $5,600 at September 30, 2008 and December 31, 2007,
respectively.
Fair
Value of Financial Instruments
–
The Company’s financial
instruments includes accounts receivable, accounts payable, notes payable and
long-term debt. The fair market value of accounts receivable and accounts
payable approximate their carrying values because their maturities are generally
less than one year. Long-term notes receivable and debt obligations are
estimated to approximate their carrying values based upon their stated interest
rates.
Impairment
of Long-Lived Assets
– In accordance with Statement of financial
Accounting Standards (“SFAS”) No. 144, Accounting for the Impairment for
Disposal of Long-Lived Assets, the Company reviews long-lived assets, such as
property and equipment, and purchased intangibles subject to amortization, for
impairment whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable,. Recoverability of assets to
be held and used is measured by a comparison of the carrying amount of an asset
to estimated undiscounted future cash flows expected to be generated by the
asset. If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized by the amount of the asset exceeds the
fair value of the asset. At December 31, 2007, the Company determined that the
fair value of the reporting entity unit exceeds its carrying amount and hence
the goodwill is not impaired.
F-7
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
1.
Summary of Significant Accounting Policies – (Continued)
Property
and equipment
–
Property and equipment are stated at cost, net of
accumulated depreciation. Depreciation is provided primarily by the
straight-line method over the estimated useful lives of the related assets
generally of five to seven years.
Income
Taxes
- The Company accounts for income taxes in accordance with
Statement of Financial Accounting Standards No. 109, “Accounting for Income
Taxes”, which requires an asset and liability approach to financial accounting
and reporting for income taxes. Deferred income tax assets and liabilities are
computed annually for differences between the financial statement and tax basis
of assets and liabilities that will result in taxable or deductible amounts in
the future based on enacted tax laws and rates applicable to the periods in
which the differences are expected to affect taxable income. Valuation
allowances are established when necessary to reduce the deferred tax assets to
the amount expected to be realized. Income tax expense is payable or refundable
for the period plus or minus the change during the period in deferred tax assets
and liabilities.
Use of
Estimates
- The preparation of financial statements in conformity with
GAAP requires management to make estimates and assumptions that affect reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ
from those estimates.
Revenue
Recognition
– We have three main sources of revenue: drug testing and
related services, training and online certification, and security services
provided by an allied company. Drug testing: we fulfill orders for
drug testing services, wherein we are responsible for the performance and data
maintenance related to employee drug testing for its clients. We do
not perform the drug tests, but we fulfill the order through our network of
third party labs and other drug testing facilities. Revenue is
recognized when the drug testing has been completed by the lab and the customer
has been invoiced for the services. We have low bad debt levels
because our policy is to deal with large well-positioned firms that pay monthly.
Because we track these company’s activities daily, we are constantly aware of
our position and therefore can demand and receive timely payments as we provide
on-going compliance services. Pursuant to EITF 99-19, we are responsible for
fulfilling a customer’s order, including whether the service is acceptable and
therefore bears the risks and rewards of principal. As such, we have
elected to record the gross amounts of the contracts. Our service
agreements rarely include multiple parts that would have a material impact on
the recognition of revenue. As such, we have created our revenue
recognition policies pursuant to EITF 00-21.
Online
training and certification: the Company has designed online testing for various
certifications which client employees must attain for their
employment. The employee takes the certification examinations online
and the client is automatically tagged for billing, which coincides with
performance of services.
Security
services provided by the Company through its allied company: the process is
handled in similar fashion to that described above for drug
testing.
Software
Development Costs
- During the period, the Company began developing a
software platform for certain exclusively internal purposes. The
Company follows the guidance set forth in Statement of Position 98-1,
Accounting for the Cost of Computer
Software Developed or Obtained for Internal Use
(SOP 98-1), in
accounting for costs incurred in the development of its on-demand application
suite. SOP 98-1 requires companies to capitalize qualifying computer
software costs that are incurred during the application development stage and
amortize them over the software’s estimated useful life.
The
Company capitalizes costs associated with developing software for internal use,
which costs primarily include salaries of developers. Direct costs
incurred in the development of software are capitalized once the preliminary
project stage is completed, management has committed to funding the projects and
completion, and use of the software for its intended purpose are
probable. The Company ceases capitalization of development costs once
the software has been substantially completed at the date of conversion and is
ready for its intended use. The estimation of useful lives requires a
significant amount of judgment related to matters, specifically, future changes
in technology. The Company believes no events or circumstances warrant revised
estimates of useful lives of the software.
F-8
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
1.
Summary of Significant Accounting Policies – (Continued)
Purchase
Accounting
- The Company completed acquisitions in 2004 and in the fourth
quarter of 2007. The purchase method of accounting requires companies to assign
values to assets and liabilities acquired based upon their fair values. In most
instances, there is not a readily defined or listed market price for individual
assets and liabilities acquired in connection with a business, including
intangible assets. The determination of fair value for assets and liabilities in
many instances requires a high degree of estimation. The valuation of
intangibles assets, in particular, is very subjective. The Company
generally uses internal cash flow models and, in certain instances, third party
valuations in estimating fair values. The use of different valuation techniques
and assumptions can change the amounts and useful lives assigned to the assets
and liabilities acquired, including goodwill and other intangible assets and
related amortization expense.
Advertising
Costs
- Advertising costs are reported in selling, general and
administrative expenses and include advertising, marketing and promotional
programs. As of December 31, 2007 and 2006, all of these costs were charged to
expenses in the period or year in which incurred. Advertising costs for the nine
months ended September 30, 2008 and the year ended December 31, 2007 were
$15,896and $10,240, respectively.
Stock
Based Compensation
–The Company accounts for stock-based employee
compensation arrangements using the fair value method in accordance with the
provisions of Statement of Financial Accounting Standards no.123(R), Share-Based
Payments, and Staff Accounting Bulletin No. 107, Share-Based Payments. The
Company accounts for the stock options issued to non-employees in accordance
with the provisions of Statement of Financial Accounting Standards No. 123,
Accounting for Stock-Based Compensation, and Emerging Issues Task Force No.
96-18, Accounting for Equity Instruments with Variable Terms That Are Issued for
Consideration other Than Employee Services Under FASB Statement No. 123. The
fair value of stock options and warrants granted to employees and non-employees
is determined using the Black-Scholes option pricing model. The Company has
adopted SFAS 123(R) and applied it in the period presented. The
Company had not issued any options to employees in the prior periods; thus there
was no impact of adopting the new standard.
Net
earnings (loss) per share
-
Basic and diluted net loss per share
information is presented under the requirements of SFAS No. 128, Earnings per
Share. Basic net loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding for the period, less shares
subject to repurchase. Diluted net loss per share reflects the potential
dilution of securities by adding other common stock equivalents, including stock
options, shares subject to repurchase, warrants and convertible notes in the
weighted-average number of common shares outstanding for a period, if dilutive.
During the nine months ended September 30, 2008 and 2007 there were no dilutive
securities. The computation of earnings (loss) per share is as
follows:
|
Nine
Months Ended
September
30,
|
|
2008
|
2007
|
Net
Income (Loss)
|
$ 145,367
|
$ 338,125
|
Weighted
average shares outstanding
|
140,654,557
|
140,399,001
|
|
|
|
Basic
Earnings (Loss) per share
|
$ 0.00
|
$
(0.00)
|
F-9
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
Recent Accounting
Pronouncements
-
In May
2008, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 163,
“Accounting for Financial Guarantee Insurance Contracts and Interpretation of
FASB Statement No. 60”. SFAS No. 163 clarifies how Statement 60
applies to financial guarantee insurance contracts, including the recognition
and measurement of premium revenue and claims liabilities. This statement also
requires expanded disclosures about financial guarantee insurance contracts.
SFAS No. 163 is effective for fiscal years beginning on or after December 15,
2008, and interim periods within those years. SFAS No. 163 has no effect on the
Company’s financial position, statements of operations, or cash flows at this
time.
In May
2008, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 162,
“The Hierarchy of Generally Accepted Accounting Principles”. SFAS No.
162 sets forth the level of authority to a given accounting pronouncement or
document by category. Where there might be conflicting guidance between two
categories, the more authoritative category will prevail. SFAS No. 162 will
become effective 60 days after the SEC approves the PCAOB’s amendments to AU
Section 411 of the AICPA Professional Standards. SFAS No. 162 has no effect on
the Company’s financial position, statements of operations, or cash flows at
this time.
In March
2008, the Financial Accounting Standards Board, or FASB, issued SFAS No. 161,
Disclosures about Derivative Instruments and Hedging Activities an amendment of
FASB Statement No. 133. This standard requires companies to provide
enhanced disclosures about (a) how and why an entity uses derivative
instruments, (b) how derivative instruments and related hedged items are
accounted for under Statement 133 and its related interpretations, and (c) how
derivative instruments and related hedged items affect an entity’s financial
position, financial performance, and cash flows. This Statement is effective for
financial statements issued for fiscal years and interim periods beginning after
November 15, 2008, with early application encouraged. The Company has not yet
adopted the provisions of SFAS No. 161, but does not expect it to have a
material impact on its consolidated financial position, results of operations or
cash flows.
In
December 2007, the SEC issued Staff Accounting Bulletin (SAB) No. 110 regarding
the use of a “simplified” method, as discussed in SAB No. 107 (SAB 107), in
developing an estimate of expected term of “plain vanilla” share options in
accordance with SFAS No. 123 (R), Share-Based Payment. In particular,
the staff indicated in SAB 107 that it will accept a company’s election to use
the simplified method, regardless of whether the company has sufficient
information to make more refined estimates of expected term. At the time SAB 107
was issued, the staff believed that more detailed external information about
employee exercise behavior (e.g., employee exercise patterns by industry and/or
other categories of companies) would, over time, become readily available to
companies. Therefore, the staff stated in SAB 107 that it would not expect a
company to use the simplified method for share option grants after December 31,
2007. The staff understands that such detailed information about employee
exercise behavior may not be widely available by December 31, 2007. Accordingly,
the staff will continue to accept, under certain circumstances, the use of the
simplified method beyond December 31, 2007. The Company currently uses the
simplified method for “plain vanilla” share options and warrants, and will
assess the impact of SAB 110 for fiscal year 2009. It is not believed that this
will have an impact on the Company’s consolidated financial position, results of
operations or cash flows.
In
December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in
Consolidated Financial Statements—an amendment of ARB No. 51. This
statement amends ARB 51 to establish accounting and reporting standards for the
noncontrolling interest in a subsidiary and for the deconsolidation of a
subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an
ownership interest in the consolidated entity that should be reported as equity
in the consolidated financial statements. Before this statement was issued,
limited guidance existed for reporting noncontrolling interests. As a result,
considerable diversity in practice existed. So-called minority interests were
reported in the consolidated statement of financial position as liabilities or
in the mezzanine section between liabilities and equity. This statement improves
comparability by eliminating that diversity. This statement is effective for
fiscal years, and interim periods within those fiscal years, beginning on or
after December 15, 2008 (that is, January 1, 2009, for entities with calendar
year-ends). Earlier adoption is prohibited. The effective date of this statement
is the same as that of the related Statement 141 (revised 2007). The Company
will adopt this Statement beginning March 1, 2009. It is not believed that this
will have an impact on the Company’s consolidated financial position, results of
operations or cash flows.
F-10
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
Recent Accounting
Pronouncements (Continued)
In
December 2007, the FASB, issued FAS No. 141 (revised 2007), Business
Combinations. ‘This Statement replaces FASB Statement No. 141, Business
Combinations, but retains the fundamental requirements in
Statement 141. This Statement establishes principles and
requirements for how the acquirer: (a) recognizes and measures in its financial
statements the identifiable assets acquired, the liabilities assumed, and any
noncontrolling interest in the acquiree; (b) recognizes and measures the
goodwill acquired in the business combination or a gain from a bargain purchase;
and (c) determines what information to disclose to enable users of the financial
statements to evaluate the nature and financial effects of the business
combination. This statement applies prospectively to business combinations for
which the acquisition date is on or after the beginning of the first annual
reporting period beginning on or after December 15, 2008. An entity may not
apply it before that date. The effective date of this statement is the same as
that of the related FASB Statement No. 160, Noncontrolling Interests in
Consolidated Financial Statements. The Company will adopt this
statement beginning March 1, 2009. It is not believed that this will have an
impact on the Company’s consolidated financial position, results of operations
or cash flows.
In
February 2007, the FASB, issued SFAS No. 159, The Fair Value Option for
Financial Assets and Liabilities—Including an Amendment of FASB Statement No.
115. This standard permits an entity to choose to measure many
financial instruments and certain other items at fair value. This option is
available to all entities. Most of the provisions in FAS 159 are elective;
however, an amendment to FAS 115 Accounting for Certain Investments in Debt and
Equity Securities applies to all entities with available for sale or trading
securities. Some requirements apply differently to entities that do not report
net income. SFAS No. 159 is effective as of the beginning of an entity’s first
fiscal year that begins after November 15, 2007. Early adoption is permitted as
of the beginning of the previous fiscal year provided that the entity makes that
choice in the first 120 days of that fiscal year and also elects to apply the
provisions of SFAS No. 157 Fair Value Measurements. The Company will
adopt SFAS No. 159 beginning March 1, 2008 and is currently evaluating the
potential impact the adoption of this pronouncement will have on its
consolidated financial statements.
In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements.
This statement defines fair value, establishes a framework for measuring
fair value in accordance with GAAP, and expands disclosures about fair value
measurements. This statement applies under other accounting pronouncements that
require or permit fair value measurements, the Board having previously concluded
in those accounting pronouncements that fair value is the relevant measurement
attribute. Accordingly, this statement does not require any new fair value
measurements. However, for some entities, the application of this statement will
change current practice. This statement is effective for financial statements
issued for fiscal years beginning after November 15, 2007, and interim periods
within those fiscal years. Earlier application is encouraged, provided that the
reporting entity has not yet issued financial statements for that fiscal year,
including financial statements for an interim period within that fiscal year.
The Company will adopt this statement March 1, 2008, and it is not believed that
this will have an impact on the Company’s consolidated financial position,
results of operations or cash flows.
In
September 2006, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 157, “Fair Value Measurements” which defines
fair value, establishes a framework for measuring fair value in accordance with
GAAP, and expands disclosures about fair value measurements. Where applicable,
SFAS No. 157 simplifies and codifies related guidance within GAAP and does
not require any new fair value measurements. SFAS No. 157 is effective for
financial statements issued for fiscal years beginning after November 15,
2007, and interim periods within those fiscal years. Earlier adoption is
encouraged. The Company does not expect the adoption of SFAS No. 157
to have a significant effect on its financial position or results of
operation.
F-11
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
2. Restatement
In
preparing the financial statements for the quarter ended March 31, 2008, the
Company determined that it had recorded excess revenue during the year ended
December 31, 2007. As the result of this error, we are
restating our financial statements (“The Restatement”) and associated
disclosures to reduce revenues. The error resulted in the over
statement of and a corresponding understatement of net loss by $241,932, for the
year ending December 31, 2007. The restatement impacted certain line items
within cash flows from operations, but had no effect on total cash flows from
operations and did not impact cash flows from financing or investing
activities.
The
restatement also affected Note 7.
The
effect of the restatement on specific items in the balance sheet is as
follows:
|
December
31, 2007
|
|
As
Previously
Reported
|
|
Adjustments
|
|
As
Restated
|
STOCKHOLDERS’
EQUITY:
|
|
|
|
|
|
Retained
earnings (deficit)
|
$
(465,703)
|
|
$ (241,932)
|
|
$
(707,635)
|
Total
Stockholders’ Equity
|
$
146,080
|
|
$ (241,932)
|
|
$
(95,852)
|
The
effect of the restatement on specific items in the statements of operations is
as follows:
|
Year
ended December 31, 2007
|
|
As
Previously
Reported
|
|
Adjustments
|
|
As
Restated
|
REVENUES:
|
$ 4,799,631
|
|
$ (241,932)
|
|
$ 4,557,699
|
GROSS
PROFIT
|
1,705,101
|
|
(241,932)
|
|
1,463,169
|
|
|
|
|
|
|
OPERATING
INCOME
|
420,190
|
|
(241,932)
|
|
178,258
|
NET
INCOME
|
345,679
|
|
(241,932)
|
|
103,747
|
The
effect of the restatement on specific items in the statements of cash flows is
as follows:
|
Year
ended December 31, 2007
|
|
As
Previously
Reported
|
|
Adjustments
|
|
As
Restated
|
OPERATING
ACTIVITIES:
|
|
|
|
|
|
Net Income
|
$ 345,679
|
|
$ (241,932)
|
|
$ 103,747
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
Increase in accounts receivable
|
(369,486)
|
|
241,932
|
|
(127,554)
|
|
|
|
|
|
|
Net
cash used in operating activities
|
62,054
|
|
-
|
|
62,054
|
F-12
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
3. Goodwill
The
Company acquired 100% of Occupational Testing, Inc. (OTI) on October 31, 2007
for $120,000 cash and a $480,000 note payable bearing interest at 1% over New
York floating prime. The note is payable in quarterly installments of
$40,000 plus accrued interest beginning January 31, 2008. The
purchase of OTI resulted in $455,210 in goodwill as an asset on the Company’s
financial statements.
4. Notes
payable
As of
September 30, 2008 and December 31, 2007, the Company had outstanding notes
payable as follows:
|
|
|
|
|
A
. Murphy, due in quarterly installments of $40,000 beginning
January 31, 2008 and bears interest at 1% over New York floating
prime
|
$ 343,066
|
$ 480,000
|
|
Bank
installment loan, payable in monthly installments of
$7,482.43
|
|
|
|
At
interest rate of 1% over prime interest
|
204,143
|
241,932
|
|
Note
payable December 31, 2008 at 4% interest per annum
|
300,000
|
|
|
Bank
line of credit due February 13, 2010 and bears interest at per annum
interest rate of 1% over prime interest
|
300,000
|
-
|
|
|
1,147,209
|
721,932
|
|
Less: current
portion
|
520,327
|
401,932
|
|
Long
term portion
|
$ 626,883
|
$320,000
|
|
|
|
|
|
Related
Party Notes Payable:
|
|
|
|
Shareholders,
due on demand, bearing interest at1.71% per annum
|
$ -
|
$100,985
|
|
Workplace
Health, due on demand, bearing interest at 4.5% per annum
|
-
|
56,000
|
|
Total
Related Party Notes Payable
|
-
|
156,985
|
|
Less: current
portion
|
-
|
156,985
|
|
Long
term portion
|
$ -
|
$ -
|
The A.
Murphy note payable is secured by all of the outstanding stock and all of the
assets of Occupational Testing, Inc. The related party notes payable
are unsecured.
The bank
loans are secured by the Company’s accounts receivable and by the personal
guarantee of the Company’s Chief Executive Officer.
Maturities
of notes payable and long-term debt for each of the years succeeding December
31, 2007 are as follows:
|
Year
ending December 31,
|
|
2008
|
$ 479,221
|
|
2009
|
257,988
|
|
2010
|
410,000
|
|
|
$ 1,147,209
|
F-13
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
5.
Stockholders’ Equity
On
September 19, 2008, the Company filed amended articles of incorporation with the
Nevada Secretary of State to increase its authorized shares from 150,000,000 to
200,000,000 shares of common stock with a par value of $0.001. The
Company had 142,699,001 shares issued and outstanding at September 30, 2008 and
140,399,001 issued and outstanding at December 31, 2007.
During
the second quarter of 2008, we issued an aggregate of 2,200,000 shares of our
common stock to our two directors and other shareholders in exchange for
the cancellation of promissory notes that we executed in favor of them in the
aggregate principal and accrued interest amount of approximately
$181,151. Because the recipients’ status as directors of ours, the
issuance of these shares is claimed to be exempt pursuant to Section 4(2) of the
Securities Act of 1933 (the “Act”).
During
the first quarter of 2008, we sold 100,000 shares of our common stock to a
single accredited investor at a per share price of $.15. This sale of
common stock is claimed to be exempt pursuant to Rule 506 of Regulation D under
the Act. No advertising or general solicitation was employed in
offering these securities. The offering and sale were made only to an
accredited investor, and subsequent transfers were restricted in accordance with
the requirements of the Act.
In the
year ended December 31, 2006, the Company sold 4,177,670 shares in private
placements to accredited investors for $307,205 in cash. This sale of
common stock is claimed to be exempt pursuant to Rule 506 of Regulation D under
the Act. No advertising or general solicitation was employed in
offering these securities. The offering and sale were made only to an
accredited investor, and subsequent transfers were restricted in accordance with
the requirements of the Act.
6.
Income Taxes
The
Company provides for income taxes under Statement of Financial Accounting
Standards No. 109, Accounting for Income Taxes. SFAS No. 109 requires the use of
an asset and liability approach in accounting for income taxes. Deferred tax
assets and liabilities are recorded based on the differences between the
financial statement and tax bases of assets and liabilities and the tax rates in
effect when these differences are expected to reverse. The Company’s predecessor
operated as entity exempt from Federal and State income taxes.
SFAS No.
109 requires the reduction of deferred tax assets by a valuation allowance if,
based on the weight of available evidence, it is more likely than not that some
or all of the deferred tax assets will not be realized.
The
provision for income taxes differs from the amounts which would be provided by
applying the statutory federal income tax rate of 39% to the net loss before
provision for income taxes for the following reasons:
|
Nine
Months Ended
September
30, 2008
|
|
Year
Ended
December
31, 2007
|
Income
tax expense at statutory rate
|
$
(54,330)
|
|
$
(134,806)
|
Valuation
allowance
|
54,330
|
|
134,806
|
Income
tax expense per books
|
$
-
|
|
$
-
|
Net
deferred tax assets consist of the following components as of:
|
Nine
Months Ended
September
30, 2008
|
|
Year
Ended December 31, 2007
|
NOL
carryover
|
$ 54,330
|
|
$
181,740
|
Valuation
allowance
|
(54,330)
|
|
(181,740)
|
Net
deferred tax asset
|
$
-
|
|
$
-
|
F-14
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
References
to September 30, 2008 are Unaudited
6.
Income Taxes –(Continued)
At
December 31, 2007, the Company had total net operating losses carried forward of
approximately $466,000 that may be offset against future taxable income through
2027. Due to the change in ownership provisions of the Tax
Reform Act of 1986, net operating loss carry forwards are subject to annual
limitations. Should a change in ownership occur net operating
loss carry forwards may be limited as to use in future years. No tax
benefit has been reported in the December 31, 2007 financial statements since
the potential tax benefit is offset by a valuation allowance of the same
amount.
In July
2006, the Financial Accounting Standards Board (“FASB”) issued Interpretation
No. 48 regarding “Accounting for Uncertainty in Income Taxes,” an interpretation
of FASB No. 109 (“FIN 48”), which defines the threshold for recognizing the
benefits of tax-return positions in the financial statements as
“more-likely-than-not” to be sustained by the taxing authorities. The Company
has reviewed its tax positions for open tax years 2005 and later and the
adoption of FIN 48 on January 1, 2007 did not result in establishing a
contingent tax liability reserve nor a corresponding charge to retained
earnings. Also, no such uncertainties were identified during 2007. The Company
has substantial tax benefits derived from its operating loss carryforwards but
has provided 100% valuation allowances against them due to uncertainties
associated with the realization of those tax benefits.
The
recognition and measurement of certain tax benefits includes estimates and
judgment by management and inherently includes subjectivity. Changes in
estimates may create volatility in the Company’s effective tax rate in future
periods when new information about particular tax positions may cause management
to change its estimates. If the Company establishes a contingent tax liability
reserve, interest and penalties related to uncertain tax positions would be
classified in general and administrative expenses.
7. Related
Party Transactions
At
December 31, 2007, loans and advances from the
Company’s two directors bore interest at 1.71% and were
unsecured, aggregated $156,985, plus accrued and unpaid
interest of $21,690, are reflected in “Loans
and advances from related party” and “Accrued
interest, related party” on the accompanying balance
sheet. These loans and accrued interest were retired during the
quarter ended June 30, 2008.
Labwire
(dba Labwire Security, Inc.) contracts with American K-9 Bomb Search, Inc.,
which is one-half owned by Labwire’s Chairman and Chief Executive Officer, to
perform security services. Labwire Security, Inc. is fully licensed
with the State of Texas. Labwire is paid a 5% commission for
the K-9 security services that it refers to Labwire Security,
Inc. The commissions received by the Company have been less than 1%
of the Company’s gross revenues.
On
November 1, 2008 Labwire Inc. entered into a commercial property lease with FM
359 LTD. for principal office space in Brookshire, Texas. Dexter Morris,
Chairman of LabWire Inc. is a principal in FM 359 LTD. A copy of the lease is
attached in the exhibit section.
F-15
MOORE
& ASSOCIATES, CHARTERED
ACCOUNTANTS AND
ADVISORS
PCAOB
REGISTERED
REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors
Labwire,
Inc.
We have
audited the accompanying restated consolidated balance sheets of Labwire, Inc.
as of December 31, 2007 and December 31, 2006, and the related restated
consolidated statements of operations, stockholders’ equity (deficit) and cash
flows for the years ended December 31, 2007 and December 31, 2006. These
financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We
conduct our audits in accordance with standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our
opinion, the restated consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Labwire,
Inc. as of December 31, 2007 and December 31, 2006, and the related restated
consolidated statements of operations, stockholders’ equity and cash flows for
the years ended December 31, 2007 and December 31, 2006, in conformity with
accounting principles generally accepted in the United States of
America.
/s/
Moore & Associates, Chartered
Moore
& Associates Chartered
Las
Vegas, Nevada
December
12, 2008
6490 West Desert Inn Rd.,
Las Vegas, NV 89146 (702) 253-7499 Fax (702) 253-7501
F-16
LABWIRE,
INC.
Consolidated
Balance Sheets
|
12/31/07
|
12/31/2006
|
|
(Restated)
|
|
ASSETS
|
|
|
CURRENT
ASSETS:
|
|
|
Cash
and cash equivalents - interest bearing
|
$ 206,520
|
$ 108,346
|
Accounts
receivable, net of allowance for doubtful accounts of $5,600 and $-0- as
of December 31, 2007 and 2006, respectively
|
860,098
|
732,544
|
Prepaid
expenses
|
20,696
|
6,148
|
Total
Current Assets
|
1,087,314
|
847,038
|
|
|
|
PROPERTY
AND EQUIPMENT:
|
|
|
Laboratory
equipment
|
53,781
|
40,371
|
Vehicles
|
7,000
|
7,000
|
Office
furniture and equipment
|
35,251
|
26,224
|
Proprietary
software
|
118,550
|
-
|
|
214,582
|
73,595
|
Less: accumulated
depreciation
|
(54,207)
|
(30,627)
|
Total
Property and Equipment
|
160,375
|
42,968
|
|
|
|
OTHER
ASSETS:
|
|
|
Goodwill
|
455,210
|
-
|
|
|
|
TOTAL
ASSETS
|
$ 1,702,899
|
$ 890,006
|
|
|
|
LIABILITIES
AND STOCKHOLDERS’ EQUITY (DEFICIT)
|
|
|
CURRENT
LIABILITIES:
|
|
|
Accounts
payable and accrued expenses
|
$ 866,796
|
$ 817,450
|
Income
taxes payable
|
24,303
|
6,008
|
Line
of credit
|
241,932
|
-
|
Current
portion of long-term debt
|
160,000
|
-
|
Notes
payable to related parties
|
156,985
|
246,600
|
Accrued
interest payable
|
7,045
|
-
|
Accrued
interest payable – related parties
|
21,690
|
19,547
|
Total
Current Liabilities
|
1,478,751
|
1,089,605
|
|
|
|
LONG-TERM
LIABILITIES:
|
|
|
Long
term-debt, less current portion above
|
320,000
|
-
|
Total
Long-term Liabilities
|
320,000
|
-
|
|
|
|
TOTAL
LIABILITIES
|
1,798,751
|
1,089,605
|
|
|
|
STOCKHOLDERS’
EQUITY (DEFICIT):
|
|
|
|
|
|
Common
stock; $0.001par value; 150,000,000 shares authorized; 140,399,001 shares
issued and outstanding at December 31, 2007 and 2006,
respectively
|
140,399
|
140,399
|
Additional
paid-in capital
|
471,384
|
471,384
|
Accumulated
deficit
|
(707,635)
|
(811,382)
|
Total
Stockholders’ Equity (Deficit)
|
(95,852)
|
(199,599)
|
|
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
|
$ 1,702,899
|
$ 890,006
|
The
accompanying notes are an integral part of these financial
statements.
F-17
LABWIRE,
INC.
Consolidated
Statements of Operations
|
For
the Year Ended
December
31,
|
|
2007
|
|
2006
|
|
(Restated)
|
|
|
|
|
|
|
REVENUES
|
$ 4,557,699
|
|
$ 3,701,742
|
COST
OF SALES
|
3,094,530
|
|
2,552,686
|
GROSS
PROFIT
|
1,463,169
|
|
1,149,056
|
|
|
|
|
OPERATING
EXPENSES:
|
|
|
|
General
and administrative expenses
|
604,545
|
|
1,010,325
|
Bad
debt expense
|
6,405
|
|
453
|
Advertising
and marketing expense
|
10,240
|
|
9,780
|
Payroll
expenses
|
663,721
|
|
597,379
|
|
|
|
|
Total
Operating Expenses
|
1,284,911
|
|
1,617,937
|
|
|
|
|
OPERATING
INCOME (LOSS)
|
178,258
|
|
(468,881
|
|
|
|
|
OTHER
INCOME (EXPENSES)
|
|
|
|
Interest expense
|
(42,634)
|
|
(26,078)
|
Interest
income
|
209
|
|
-
|
Total
Other Income (Expenses)
|
(42,425)
|
|
(26,078)
|
|
|
|
|
NET
INCOME (LOSS) BEFORE TAXES
|
135,833
|
|
(494,959)
|
|
|
|
|
INCOME
TAX EXPENSE
|
32,086
|
|
6,022
|
|
|
|
|
NET
INCOME (LOSS)
|
$ 103,747
|
|
$
(500,981)
|
|
|
|
|
BASIC
EARNINGS (LOSS) PER SHARE
|
$ 0.0007
|
|
$
(0.0036)
|
|
|
|
|
WEIGHTED
AVERAGE NUMBER OF SHARES OUTSTANDING
|
140,399,001
|
|
138,315,665
|
The
accompanying notes are an integral part of these financial
statements.
F-18
LABWIRE,
INC.
Consolidated
Statement of Stockholders’ Equity (Deficit)
DESCRIPTION
|
Common
Shares
|
Stock
Amount
|
|
Additional
Paid-In
Capital
|
|
Accumulated
Deficit
|
|
Total
Stockholders’
Equity
(Deficit)
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2005
|
136,232,330
|
$136,232
|
|
$168,346
|
|
$(310,401)
|
|
$(5,823)
|
|
|
|
|
|
|
|
|
|
Common
shares issued for cash
|
4,166,671
|
4,167
|
|
303,038
|
|
-
|
|
307,205
|
|
|
|
|
|
|
|
|
|
Net
loss for the year ended
|
-
|
-
|
|
-
|
|
(500,981)
|
|
(500,981)
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2006
|
140,399,001
|
140,399
|
|
471,384
|
|
(811,382)
|
|
(199,599)
|
|
|
|
|
|
|
|
|
|
Net
income for the year ended December 31, 2007 (Restated)
|
-
|
-
|
|
-
|
|
103,747
|
|
103,747
|
|
|
|
|
|
|
|
|
|
Balance,
December 31, 2007 (Restated)
|
140,399,001
|
$140,399
|
|
$471,384
|
|
$(707,635)
|
|
$(95,852)
|
The
accompanying notes are an integral part of these financial
statements.
F-19
LABWIRE,
INC.
Consolidated
Statements of Cash Flows
|
|
For
the Year Ended
December
31,
|
|
|
2007
|
|
|
2006
|
|
|
(Restated)
|
|
|
|
OPERATING
ACTIVITIES
|
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss)
|
|
$ 103,747
|
|
|
$
(500,981)
|
Adjustments
to reconcile net income (loss) to net cash provided (used) by operating
activities:
|
|
|
|
|
|
Depreciation
|
|
23,580
|
|
|
16,022
|
Changes
in operating assets and liabilities
|
|
|
|
|
|
(Increase) decrease in accounts receivable
|
|
(127,554)
|
|
|
184,511
|
(Increase) decrease in prepaid expenses
|
|
(14,548)
|
|
|
(6,148)
|
|
|
|
|
|
|
Increase
(decrease) in accounts payable and accrued expenses
|
|
49,346
|
|
|
113,757
|
Increase
(decrease) in accrued interest payable
|
|
9,188
|
|
|
-
|
Increase
(decrease) in income tax payable
|
|
18,295
|
|
|
-
|
Net
Cash Provided by (Used) in Operating Activities
|
|
62,054
|
|
|
(192,839)
|
|
|
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES
|
|
|
|
|
|
Purchase
of property and equipment
|
|
(22,437)
|
|
|
(16,474)
|
Development
of Software
|
|
(118,550)
|
|
|
-
|
Acquisition
goodwill
|
|
(455,210)
|
|
|
-
|
Net
Cash Used in Investing Activities
|
|
(596,197)
|
|
|
(16,474)
|
|
|
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
Repayment
of notes payable
|
|
(59,890)
|
|
|
(65,000)
|
Increase
in bank line of credit
|
|
241,932
|
|
|
-
|
Increase
in notes payable
|
|
450,275
|
|
|
|
Sale
of common stock for cash
|
|
-
|
|
|
307,205
|
Net
Cash Provided by Financing Activities
|
|
632,317
|
|
|
242,205
|
|
|
|
|
|
|
NET
INCREASE IN CASH
|
|
98,174
|
|
|
32,892
|
|
|
|
|
|
|
CASH
AT BEGINNING OF YEAR
|
|
108,346
|
|
|
75,454
|
|
|
|
|
|
|
CASH
AT END OF YEAR
|
|
$ 206,520
|
|
|
$ 108,346
|
|
|
|
|
|
|
CASH
PAID FOR:
|
|
|
|
|
|
Interest
|
|
$ 31,305
|
|
|
$ 19,378
|
Income
Taxes
|
|
$ -
|
|
|
$ 4,840
|
The
accompanying notes are an integral part of these financial
statements.
F-20
Labwire,
Inc.
Notes to
Consolidated Financial Statements
1. Summary of Significant Accounting
Policies
Nature of
Operations
- Labwire, Inc. (referred to herein as “the Company”), was
incorporated in Nevada on October 8, 2004. The Company was established as an
employee screening company specializing in drug testing, background
investigations, employee training, on-line certification and security, with a
client base of large US and European corporations. It provides
compliance services for Department Of Transportation (49 CFR Part 40) and
Federal Trade Commission (Fair Credit Reporting Act) governed
programs.
Basis of
Consolidation
– The consolidated financial statements include the
accounts of the Company and its wholly-owned subsidiary. All
intercompany balances and transactions have been eliminated in
consolidation.
Basis of
Presentation
-
The accompanying financial statements have been
prepared on the accrual basis of accounting in accordance with accounting
principles generally accepted in the United States of America (“GAAP”).
Significant accounting principles followed by the Company and the methods of
applying those principles, which materially affect the determination of
financial position and cash flows, are summarized below.
Cash and
Cash Equivalents
- For purposes of the statement of cash flows, the
Company considers all highly liquid instruments with original maturities of
ninety days or less, to be cash equivalents.
Allowance
for Uncollectible Receivables
-The allowance for all probable
uncollectible receivables is based on a combination of historical data, cash
payment trends, specific customer issues, write-off trends, general economic
conditions and other factors. These factors are continuously monitored by
management to arrive at an estimate for the amount of accounts receivable that
may ultimately be uncollectible. In circumstances where the Company is aware of
a specific customer’s inability to meet its financial obligations, the Company
records a specific allowance for bad debts against amounts due to reduce the net
recognized receivable to the amount it reasonably believes will be collected.
This analysis requires making significant estimates, and changes in facts and
circumstances could result in material changes in the allowance for
uncollectible receivables. The Company’s allowance for uncollectible
receivables was $5,600 and $-0- at December 31, 2007 and December 2006,
respectively.
Fair
Value of Financial Instruments
- The Company’s financial instruments
includes accounts receivable, accounts payable, notes payable and long-term
debt. The fair market value of accounts receivable and accounts payable
approximate their carrying values because their maturities are generally less
than one year. Long-term notes receivable and debt obligations are estimated to
approximate their carrying values based upon their stated interest
rates.
Impairment
of Long-Lived Assets
- The Company reviews long-lived assets, such
as property and equipment, and purchased intangibles subject to amortization,
for impairment whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable, in accordance with Statement
of financial Accounting Standards (“SFAS”) No. 144, Accounting for the
Impairment for Disposal of Long-Lived Assets. Recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to
estimated undiscounted future cash flows expected to be generated by the asset.
If the carrying amount of an asset exceeds its estimated future cash flows, an
impairment charge is recognized by the amount of the asset exceeds the fair
value of the asset.
At
December 31, 2007, the Company determined that the fair value of the reporting
entity unit exceeds its carrying amount and hence the goodwill is not
impaired.
Property
and equipment
- Property and equipment are stated at cost, net of
accumulated depreciation. Depreciation is provided primarily by the
straight-line method over the estimated useful lives of the related assets
generally of five to seven years.
F-21
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
1.
Summary of Significant Accounting Policies – (Continued)
Income
Taxes
-The Company accounts for income taxes in accordance with Statement
of Financial Accounting Standards No. 109, “Accounting for Income Taxes”, which
requires an asset and liability approach to financial accounting and reporting
for income taxes. Deferred income tax assets and liabilities are computed
annually for differences between the financial statement and tax basis of assets
and liabilities that will result in taxable or deductible amounts in the future
based on enacted tax laws and rates applicable to the periods in which the
differences are expected to affect taxable income. Valuation allowances are
established when necessary to reduce the deferred tax assets to the amount
expected to be realized. Income tax expense is payable or refundable for the
period plus or minus the change during the period in deferred tax assets and
liabilities.
Use of
Estimates
- The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Revenue
Recognition
– We have three main sources of revenue: drug testing and
related services, training and online certification, and security services
provided by an allied company. Drug testing: we fulfill orders for
drug testing services, wherein we are responsible for the performance and data
maintenance related to employee drug testing for its clients. We do
not perform the drug tests, but we fulfill the order through our network of
third party labs and other drug testing facilities. Revenue is
recognized when the drug testing has been completed by the lab and the customer
has been invoiced for the services. We have low bad debt levels
because our policy is to deal with large well-positioned firms that pay monthly.
Because we track these company’s activities daily, we are constantly aware of
our position and therefore can demand and receive timely payments as we provide
on-going compliance services. Pursuant to EITF 99-19, we are responsible for
fulfilling a customer’s order, including whether the service is acceptable and
therefore bears the risks and rewards of principal. As such, we have
elected to record the gross amounts of the contracts. Our service
agreements rarely include multiple parts that would have a material impact on
the recognition of revenue. As such, we have created our revenue
recognition policies pursuant to EITF 00-21.
Online
training and certification: the Company has designed online testing for various
certifications which client employees must attain for their
employment. The employee takes the certification examinations online
and the client is automatically tagged for billing, which coincides with
performance of services.
Security
services provided by the Company through its allied company: the process is
handled in similar fashion to that described above for drug
testing.
Software
Development Costs
- During the period, the Company began developing a
software platform for certain exclusively internal purposes. The
Company follows the guidance set forth in Statement of Position 98-1,
Accounting for the Cost of Computer
Software Developed or Obtained for Internal Use
(SOP 98-1), in
accounting for costs incurred in the development of its on-demand application
suite. SOP 98-1 requires companies to capitalize qualifying computer
software costs that are incurred during the application development stage and
amortize them over the software’s estimated useful life.
The
Company capitalizes costs associated with developing software for internal use,
which costs primarily include salaries of developers. Direct costs
incurred in the development of software are capitalized once the preliminary
project stage is completed, management has committed to funding the project and
completion, and use of the software for its intended purpose are
probable. The Company ceases capitalization of development costs once
the software has been substantially completed and is ready for its intended use.
The estimation of useful lives requires a significant amount of judgment related
to matters, specifically, future changes in technology. The Company believes
there have not been any events or circumstances that warrant revised estimates
of useful lives of the software.
F-22
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
(Continued)
1.
Summary of Significant Accounting Policies – (Continued)
Purchase
Accounting
- The Company completed acquisitions in 2004 and in the fourth
quarter of 2007. The purchase method of accounting requires companies to assign
values to assets and liabilities acquired based upon their fair values. In most
instances, there is not a readily defined or listed market price for individual
assets and liabilities acquired in connection with a business, including
intangible assets. The determination of fair value for assets and liabilities in
many instances requires a high degree of estimation. The valuation of
intangibles assets, in particular, is very subjective. The Company
generally uses internal cash flow models and, in certain instances, third party
valuations in estimating fair values. The use of different valuation techniques
and assumptions can change the amounts and useful lives assigned to the assets
and liabilities acquired, including goodwill and other intangible assets and
related amortization expense.
Advertising
Costs
- Advertising costs are reported in selling, general and
administrative expenses and include advertising, marketing and promotional
programs. As of December 31, 2007 and 2006, all of these costs were charged to
expenses in the period or year in which incurred. Advertising costs for the
years ended December 31, 2007 and 2006 were $10,240 and $9,780,
respectively.
Stock
Options
- The Company accounts for stock options issued to employees in
accordance with APB No.25. The Company has elected to adopt the
disclosure requirements of SFAS No.123 “Accounting for Stock-based
Compensation”. This statement requires that the Company provide proforma
information regarding net income (loss) and income (loss) per share as if
compensation cost for the Company’s stock options granted had been determined in
accordance with the fair value based method prescribed in SFAS No. 123.
Additionally, SFAS No. 123 generally requires that the Company record options
issued to non-employees, based on the fair value of the options.
Stock
Based Compensation
-ASRC accounts for stock-based employee compensation
arrangements using the fair value method in accordance with the provisions of
Statement of Financial Accounting Standards no.123(R), Share-Based Payments, and
Staff Accounting Bulletin No. 107, Share-Based Payments. The Company accounts
for the stock options issued to non-employees in accordance with the provisions
of Statement of Financial Accounting Standards No. 123, Accounting for
Stock-Based Compensation, and Emerging Issues Task Force No. 96-18, Accounting
for Equity Instruments with Variable Terms That Are Issued for Consideration
other Than Employee Services under FASB Statement No. 123. The fair value of
stock options and warrants granted to employees and non-employees is determined
using the Black-Scholes option pricing model. The Company has adopted SFAS
123(R) and applied it in the period presented. The Company had not
issued any options to employees in the prior periods; thus there was no impact
of adopting the new standard.
Net
earnings (loss) per share
- Basic and diluted net loss per share
information is presented under the requirements of SFAS No. 128, Earnings per
Share. Basic net loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding for the period, less shares
subject to repurchase. Diluted net loss per share reflects the potential
dilution of securities by adding other common stock equivalents, including stock
options, shares subject to repurchase, warrants and convertible notes in the
weighted-average number of common shares outstanding for a period, if dilutive.
During the years ended December 31, 2007 and 2006 there were no dilutive
securities. The computation of earnings (loss) per share is as
follows:
|
Year
Ended
December
31,
|
|
2007
|
2006
|
Net
Income (Loss)
|
$
103,747
|
$
(500,981)
|
Weighted
average shares outstanding
|
140,399,001
|
138,315,665
|
|
|
|
Basic
Earnings (Loss) per share
|
$
0.0007
|
$
(0.0036)
|
F-23
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
(Continued)
1.
Summary of Significant Accounting Policies – (Continued)
Recent
Accounting Pronouncements
In
September 2006, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 157, “Fair Value Measurements” which defines
fair value, establishes a framework for measuring fair value in accordance with
GAAP, and expands disclosures about fair value measurements. Where applicable,
SFAS No. 157 simplifies and codifies related guidance within GAAP and does
not require any new fair value measurements. SFAS No. 157 is effective for
financial statements issued for fiscal years beginning after November 15,
2007, and interim periods within those fiscal years. Earlier adoption is
encouraged. The Company does not expect the adoption of SFAS No. 157
to have a significant effect on its financial position or results of
operation.
In
February 2007, the FASB issued SFAS NO. 159, The Fair Value Option for Financial
Assets and Financial Liabilities-Including an amendment of FASB Statement No.
115. This statement permits entities to choose to measure many
financial instruments and certain items at fair value. The objective
is to improve the financial reporting by providing entities with the opportunity
to mitigate volatility in reported earnings caused by measuring related assets
and liabilities differently without having to apply complex hedge accounting
provisions. This statement is expected to expand the use of fair
value measurement objectives for accounting for financial
instruments. This statement is effective as of the beginning of an
entity’s first fiscal year that begins after November 15, 2007.
In
December 2007, the FASB issued SFAS 160, Non-controlling Interest in
Consolidated Financial Statements-an amendment of ARB No. 51. This statement
amends ARB 51 to establish accounting and reporting standards for the
non-controlling interest in a subsidiary and for the deconsolidation of a
subsidiary. It also changes the way the consolidated income statement
is presented for non-controlling interest. This statement improves comparability
by eliminating diversity of methods. This statement also requires
expanded disclosure. The Company does not expect the adoption of SFAS
No. 160 to have a significant effect on its financial position or results
of operation.
In March
2008, the FASB issued SFAS 161, Disclosures about Derivative Instruments and
Hedging Activities--an amendment of FASB Statement No. 133. This statement is
intended to enhance the disclosure requirements for derivative instruments and
hedging activities as required by SFAS 133. The Company is currently
evaluating the impact, if any, the adoption of SFAS 161 will have on its
disclosure requirements.
In May
2008, the FASB issued SFAS 162, The Hierarchy of Generally Accepted Accounting
Principles. This Statement identifies the
sources of accounting principles and the
framework for selecting the principles
to be used in the preparation of financial statements of nongovernmental
entities that are presented in conformity with generally accepted
accounting principles (GAAP) in the United States (the GAAP
hierarchy). The Company is currently evaluating the impact, if any,
the adoption of SFAS 161 will have on its disclosure requirements.
F-24
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
(Continued)
2. Restatement
In
preparing the financial statements for the quarter ended March 31, 2008, the
Company determined that it had recorded excess revenue during the year ended
December 31, 2007. As the result of this error, we are
restating our financial statements (“The Restatement”) and associated
disclosures to reduce revenues. The error resulted in the over
statement of and a corresponding understatement of net loss by $241,932, for the
year ending December 31, 2007. The restatement impacted certain line items
within cash flows from operations, but had no effect on total cash flows from
operations and did not impact cash flows from financing or investing
activities.
The
restatement also affected Note 7.
The
effect of the restatement on specific items in the balance sheet is as
follows:
|
December
31, 2007
|
|
As
Previously Reported
|
|
Adjustments
|
|
As
Restated
|
STOCKHOLDERS’
EQUITY:
|
|
|
|
|
|
Retained
earnings (deficit)
|
$
(465,703)
|
|
$
(241,932)
|
|
$
(707,635)
|
Total
Stockholders’ Equity
|
$
146,080
|
|
$
(241,932)
|
|
$
(95,852)
|
The
effect of the restatement on specific items in the statements of operations is
as follows:
|
Year
ended December 31, 2007
|
|
As
Previously
Reported
|
Adjustments
|
As
Restated
|
REVENUES:
|
$4,799,631
|
$(241,932)
|
$4,557,699
|
GROSS
PROFIT
|
1,705,101
|
(241,932)
|
1,463,169
|
|
|
|
|
OPERATING
INCOME
|
420,190
|
(241,932)
|
178,258
|
NET
INCOME
|
345,679
|
(241,932)
|
103,747
|
The
effect of the restatement on specific items in the statements of cash flows is
as follows:
|
Year
ended December 31, 2007
|
|
As
Previously Reported
|
|
Adjustments
|
|
As
Restated
|
OPERATING
ACTIVITIES:
|
|
|
|
|
|
Net
Income
|
$ 345,679
|
|
$
(241,932)
|
|
$103,747
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
Increase
in accounts receivable
|
(369,486)
|
|
241,932
|
|
(127,554)
|
|
|
|
|
|
|
Net
cash used in operating activities
|
62,054
|
|
-
|
|
62,054
|
F-25
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
(Continued)
3. Goodwill
The
Company acquired 100% of Occupational Testing, Inc. (OTI) on October 31, 2007
for $120,000 cash and a $480,000 note bearing interest at 1% over New York
floating prime. The note is payable in quarterly installments of
$40,000 plus accrued interest beginning January 31, 2008. The
purchase of OTI resulted in $455,210 in goodwill as an asset on the Company’s
financial statements.
4. Line
of credit
On
February 13, 2007, the Company established a $300,000 revolving line of credit
with Frost Bank that matures on February 13, 2008. The interest rate
on the outstanding balance of the revolving line of credit is a floating prime
plus 1% and is due on the 24
th
of each
month. The principal balance owing by the Company at December 31, 2007 was
$241,933 and accrued interest payable was $-0-. The Company had $58,067
available on the revolving line of credit at December 31, 2007. This
line of credit is secured by a UCC Financing statement signed by the Company in
favor of the lender and by the personal guarantee of the Company’s Chief
Executive Officer.
5. Long-term
notes payable
As of
December 31, 2007 and 2006, the Company had notes payable totaling $636,985 as
follows:
|
2007
|
2006
|
A
. Murphy, due in quarterly installments of $40,000 beginning
January 31, 2008 and bears interest at 1% over New York floating
prime
|
$480,000
|
$ -
|
|
|
|
Less: current
portion
|
160,000
|
-
|
|
$320,000
|
$ -
|
|
|
|
Related
Party Notes Payable:
|
|
|
Shareholders,
due on demand, bearing interest at1.71% per annum
|
$100,985
|
$190,600
|
|
|
|
Workplace
Health, due on demand, bearing interest at 4.5% per annum
|
56,000
|
56,000
|
|
156,985
|
246,600
|
|
|
|
Less: current
portion
|
156,985
|
246,600
|
|
$ -
|
$ -
|
The A.
Murphy note payable is secured by all of the outstanding stock and all of the
assets of Occupational Testing, Inc. The related party notes payable
are unsecured.
Maturities
of notes payable and long-term debt for each of the years succeeding December
31, 2007 are as follows:
Year
ending December 31,
|
2008
|
$ 316,985
|
2009
|
160,000
|
2010
|
160,000
|
|
$ 636,985
|
F-26
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
(Continued)
6.
Stockholders’ Equity
The
Company is authorized to issue 150,000,000 shares of common stock with a par
value of $.001 per share. The Company had 140,399,000 shares issued
and outstanding at September 30, 2007, December 31, 2006 and 2005,
respectively.
In the
year ended December 31, 2006, the Company sold 4,177,670 shares in private
placements to accredited investors for $307,205 in cash.
7.
Income Taxes
The
Company provides for income taxes under Statement of Financial Accounting
Standards No. 109, Accounting for Income Taxes. SFAS No. 109 requires the use of
an asset and liability approach in accounting for income taxes. Deferred tax
assets and liabilities are recorded based on the differences between the
financial statement and tax bases of assets and liabilities and the tax rates in
effect when these differences are expected to reverse. The Company’s predecessor
operated as entity exempt from Federal and State income taxes.
SFAS No.
109 requires the reduction of deferred tax assets by a valuation allowance if,
based on the weight of available evidence, it is more likely than not that some
or all of the deferred tax assets will not be realized.
The
provision for income taxes differs from the amounts which would be provided by
applying the statutory federal income tax rate of 39% to the net loss before
provision for income taxes for the following reasons:
|
December
31, 2007
|
|
December
31, 2006
|
Income
tax expense at statutory rate
|
$ (134,806)
|
|
$ (168,286)
|
Valuation
allowance
|
134,806
|
|
168,286
|
Income
tax expense per books
|
$ -
|
|
$
-
|
Net
deferred tax assets consist of the following components as of:
|
December
31, 2007
|
|
December
31, 2006
|
NOL
carryover
|
$ 181,740
|
|
$ 168,286
|
Valuation
allowance
|
(181,740)
|
|
(168,286)
|
Net
deferred tax asset
|
$ -
|
|
$
-
|
At
December 31, 2007, the Company had total net operating losses carried forward of
approximately $466,000 that may be offset against future taxable income through
2027. Due to the change in ownership provisions of the Tax
Reform Act of 1986, net operating loss carry forwards are subject to annual
limitations. Should a change in ownership occur, net operating
loss carry forwards may be limited as to use in future years. No tax
benefit has been reported in the December 31, 2007 financial statements since
the potential tax benefit is offset by a valuation allowance of the same
amount.
F-27
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
7.
Income Taxes - Continued
In July
2006, the Financial Accounting Standards Board (“FASB”) issued Interpretation
No. 48 regarding “Accounting for Uncertainty in Income Taxes,” an interpretation
of FASB No. 109 (“FIN 48”), which defines the threshold for recognizing the
benefits of tax-return positions in the financial statements as
“more-likely-than-not” to be sustained by the taxing authorities. The Company
has reviewed its tax positions for open tax years 2005 and later and the
adoption of FIN 48 on January 1, 2007 did not result in establishing a
contingent tax liability reserve nor a corresponding charge to retained
earnings. Also, no such uncertainties were identified during 2007. The Company
has substantial tax benefits derived from its operating loss carryforwards but
has provided 100% valuation allowances against them due to uncertainties
associated with the realization of those tax benefits.
The
recognition and measurement of certain tax benefits includes estimates and
judgment by management and inherently includes subjectivity. Changes in
estimates may create volatility in the Company’s effective tax rate in future
periods from obtaining new information about particular tax positions that may
cause management to change its estimates. If the Company would establish a
contingent tax liability reserve, interest and penalties related to uncertain
tax positions would be classified in general and administrative
expenses.
8. Related
Party Transactions
As
of December 31, 2007, these loans
and advances, which bear interest at 1.71% and are
unsecured, aggregated $156,985, plus accrued and unpaid
interest of $21,690, and are reflected in
“Loans and advances from related party” and
“Accrued interest, related party” on the accompanying balance
sheet.
9. Acquisitions
On
October 31, 2007, the Company acquired Occupational Testing, Inc. The
acquisition cost, funded from our existing cash balances and by the issuance of
a promissory note to the shareholder of Occupational Testing, Inc., are shown by
the following table which summarizes the purchase consideration and fair values
of the assets acquired at the date of acquisition:
Purchase
Price Consideration
|
|
|
Cash
paid to the shareholder of Occupational Testing, Inc.
|
|
$ 120,000
|
Promissory
Note to the shareholder of Occupational Testing, Inc.
|
|
480,000
|
Acquisition
costs
|
|
10,960
|
Total
consideration paid
|
|
$ 610,960
|
|
|
|
Net
Assets Acquired
|
|
|
Cash
and cash equivalents
|
|
$ 42,711
|
Accounts
receivable
|
|
105,063
|
Fixed
assets
|
|
13,410
|
Other
assets
|
|
780
|
Goodwill
|
|
455,210
|
Liabilities
assumed
|
|
(6,214)
|
Total
net assets
|
|
$ 610,960
|
We have
included the results of operations for Occupational Testing, Inc. in our
financial statements since October 31, 2007.
F-28
Labwire,
Inc.
Notes to
the Consolidated Financial Statements
(Continued)
10. Subsequent
Events
On
February 13, 2008, the Company renewed its revolving loan agreement as a term
note with a maturity date of March 4, 2011 at an interest rate of 6.25% per
annum.
On March
4, 2008, the Company entered into a revolving loan agreement with a maturity
date of February 13, 2010 at an interest rate of 1% over the rate that the
Lender charges, or would charge, on 90-day unsecured loans to the most
creditworthy corporate customers.
On May
27, 2008, the Board of Directors and shareholders owning approximately 85% of
the Company’s issued and outstanding common shares voted to increase its
authorized shares of common stock from 150,000,000 to 200,000,000 at par value
of $0.001 per share.
11.
Pro Forma Results (Unaudited)
The
following table reflects unaudited pro forma results of operations assuming that
the Occupational Testing, Inc. acquisition had occurred on January 1,
2006:
|
Year
Ended
December
31,
|
|
2007
|
2006
|
Revenue
|
$ 5,506,771
|
$ 4,415,478
|
Net
income (loss)
|
$ 485,568
|
$ (397,234)
|
|
|
|
Net
income (loss) per share
|
$ 0.0035
|
$ (0.0029)
|
F-29
Labwire (CE) (USOTC:LBWR)
過去 株価チャート
から 10 2024 まで 11 2024
Labwire (CE) (USOTC:LBWR)
過去 株価チャート
から 11 2023 まで 11 2024